Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Full Year Results

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231129:nRSc9864Ua&default-theme=true

RNS Number : 9864U  Benchmark Holdings PLC  29 November 2023

29 November 2023

 

Benchmark Holdings plc

 

("Benchmark", the "Company" or the "Group")

 

Full Year Results for the Financial Year ended 30 September 2023

 

Third consecutive year of financial and strategic delivery

Strategic steps to further streamline and integrate the Group, positioning it
for the next phase of growth

 

Benchmark, the aquaculture biotechnology company, announces its full year
audited results for the year ended 30 September 2023 (the "period").

 

Financial highlights - Revenue growth and improved profitability with steady
progress in all business areas

 

·    Revenue from continuing operations increase of 7% (+7% CER**):

o  Advanced Nutrition - strong performance in challenging shrimp markets,
further strengthening our leading market position; revenues -2% (-7% CER)

o  Genetics - strong performance with record salmon egg sales in our three
facilities - Iceland, Norway and Chile; revenue growth of +14% (+20% CER)

o  Health - growing adoption of sea lice solution Ectosan® Vet and
CleanTreat® and increase in sales of Salmosan® Vet resulting in revenue
growth of 27% (+29% CER)

·    15% increase (+16% CER) in Adjusted EBITDA from continuing
operations, excluding fair value movements from biological assets, as a result
of higher revenues and tight cost control

·    Adjusted EBITDA(1) margin from continuing operations excluding fair
value uplift from biological assets increased to 21% (FY22: 20%)

·    Significant progress towards profitability:

o  Adjusted operating profit from continuing operations increased by 36% to
£14.6m (FY22: £10.7m)

o  Loss before tax from continuing operations reduced to £12.7m (FY22
restated: £21.4m) due to the positive trading result and lower finance costs,
partially offset by higher exceptional items

·    Significant improvement in cash generation with operational cash flow
close to double to £20m (FY22: £10.8m); cash conversion(4) increased from
35% to 58%

·    Net debt(3) reduced to £65.5m (FY22: £73.7m)

·    Cash and cash equivalents of £35.6m and available liquidity of
£48.8m

·    At 27 November, cash and cash equivalents of £29.3m and available
liquidity of £41.5m

 

 £m                                                                           FY 2023  FY 2022     % AER  % CER**

                                                                                       restated*
 Revenue from continuing operations                                           169.5    157.7       7%     7%
 Adjusted
 Adjusted EBITDA(1) from continuing operations                                35.5     32.6        9%     11%
 Adjusted EBITDA from continuing operations excluding fair value uplift from  35.6     31.0        15%    16%
 biological assets
 Adjusted operating profit(2) from continuing operations                      14.6     10.7        36%    41%
 Statutory
 Operating loss from continuing operations                                    (5.3)    (6.2)       15%    22%
 Loss before tax from continuing operations                                   (12.7)   (21.4)      41%    44%
 Loss for the period including discontinued operations                        (21.6)   (30.5)      29%    31%
 Basic loss per share (p)                                                     (3.16)   (4.60)      31%
 Net debt(3)                                                                  (65.5)   (73.7)
 Net debt excluding lease liabilities                                         (45.6)   (47.5)

 

* 2022 figures have been restated to reflect changes to the ongoing continuing
business during the year following the disposal of the tilapia business

** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related items.

(2) Adjusted Operating Profit is operating loss before exceptional items
including acquisition related items and amortisation of intangible assets
excluding development costs

(3) Net debt is cash and cash equivalents less loans and borrowings

(4) Cash generated from operations after working capital and taxes as
percentage of Adj. EBITDA

 

 

 Business Area Performance (continuing operations)                  FY 2023  FY 2022      % AER   % CER**

 £m                                                                          restated *
 Revenue
 Genetics                                                           65.5     57.4         14%     20%
 Advanced Nutrition                                                 78.5     80.3         (2%)    (7%)
 Animal Health                                                      25.5     20.1         27%     29%
 Adjusted EBITDA(1)
 Genetics                                                           15.7     17.4         (10%)   (1%)
 -       excluding fair value movements in biological assets        15.8     15.8         0%      8%
 Advanced Nutrition                                                 18.4     19.0         (3%)    (8%)
 Animal Health                                                      4.8      0.1          4,295%  4,165%

 

** Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates

(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items including acquisition
related expenditure.

 

Operational highlights

 

Advanced Nutrition - commercial focus and programme of efficiencies translate
into business resilience and stronger market position

 

·    Continued commercial focus leveraging technical services capabilities
and adapting to market conditions

·    Commenced implementation of structured programme of operational
efficiencies focused on automation, supply chain integration, and digitalised
data management

·    Continued innovation with launch of first AI-enabled live feed
counting tool SnappArt and establishment of new R&D collaborations in
Ecuador and Singapore

 

Genetics - continue to strengthen global position in salmon eggs

·     Record volume of salmon eggs of 335 million, a 15% increase

·     Acquired remaining 10.52% minority interest in Benchmark Genetics
Iceland (50% of Group's salmon egg production) for €9m

·     Doubling of sales demonstrate growing commercial traction in Chile
where our facilities obtained disease-free compartment status enabling future
exports

·     Development of a new shrimp genetics product portfolio underway;
shrimp activities reorganised and aligned to realise synergies with Advanced
Nutrition

·     Divestment of tilapia business through an MBO

·     Expanded R&D team with a focus on reproductive technologies
paving the way for breakthrough developments in sterility and gene editing

 

Health - increased adoption of Ectosan® Vet and CleanTreat®

·     Increased adoption of Ectosan® Vet and CleanTreat® by large and
small producers along the entire Norwegian coastline

·     Further progress in the development of a new business model and
configuration for CleanTreat® to integrate the system into customers'
wellboat infrastructure

·     Good year for our second sea lice treatment, Salmosan® Vet, which
showed a resurgence of demand driven mainly by label changes which allow
longer use in certain territories

Group - further streamlining and integration creating opportunities for
commercial and cost synergies

·     Important strategic alignment bringing together our salmon
activities under the leadership of our Head of Genetics and our shrimp
activities under the leadership of our Head of Advanced Nutrition. This
customer-centric structure will enable us to increase our commercial impact
with a combined offering and customer network and realise synergies

·     Continued progress on sustainability initiatives including energy
efficiency and GHG emissions, certification and development of novel feed
ingredients. ESG rating improvement by MSCI to AA

·     Looking forward the Group remains focused on its four strategic
pillars:

o  Maintain and grow its leadership position in established markets

o  Expand its business through the launch of new products and development of
key growth vectors

o  Continue to embed the "One Benchmark" culture and integrate the Group to
realise synergies

o  Pursue strategic opportunities adhering to strict criteria

 

Current trading and outlook - positive momentum trading in-line with
management expectations

·     Good start to FY24 and positive momentum in the business

o  Good visibility of revenues in salmon genetics

o  Early indications of improvement in the shrimp markets

o  Increase in sea lice treatments post period end with good capacity
utilisation of CleanTreat®; expect normal seasonality

Trond Williksen, CEO, commented:

 

"We delivered good growth in revenue and Adjusted EBITDA, and increased cash
conversion, despite challenging conditions in the global shrimp markets. This
demonstrates the strength of our business and the agility of our organisation
to adapt - mitigating the impact of a soft market and taking advantage of
commercial opportunities to further consolidate our leading market position.
The new financial year has also started well and in line with our
expectations, with positive momentum in our three business areas.

 

"Since the end of FY20 when we completed the Group restructuring, we have been
building a track record of growth and improved profitability, reflected by
revenues and Adjusted EBITDA from continuing operations which have increased
over this period by 61% and 128%, respectively.

 

"Benchmark is uniquely positioned in an industry that is structurally growing
supported by attractive megatrends. With a clear strategy and an integrated
commercial network covering the main aquaculture species, we have significant
opportunity to deliver growth and shareholders returns. We will continue the
execution of our strategy to realise the value inherent in our business for
the benefit of all our stakeholders."

 

Presentation for analysts and institutional investors at 8am GMT

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a presentation for analysts and institutional investors on
the day at 08.00 GMT (09.00 CET).

 

The presentation will be held in person at Haakon Vlls Gate 2, Oslo, Norway.
To register your interest, please contact benchmark@mhpgroup.com
(mailto:benchmark@mhpgroup.com)

 

A live webcast of the presentation will be available for analysts and
investors to join remotely at the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20231129_1
(https://protect-eu.mimecast.com/s/15WXC98RjU4AznQtoqXNf?domain=channel.royalcast.com)

 

Equity Development webcast for retail investors at 12pm GMT

 

Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host a second webcast for retail investors and wealth managers at
12.00 GMT (13:00 CET). The webcast is open to all existing and potential
shareholders.

 

To register please visit:
https://www.equitydevelopment.co.uk/news-and-events/benchmark-investor-presentation-29november2023
(https://protect-eu.mimecast.com/s/5rvkClOj0cRmzPPHGCXA2?domain=equitydevelopment.co.uk)

 

 

Enquiries

 

 Benchmark Holdings plc                         Tel:  0114 240 9939
 Trond Williksen, CEO
 Septima Maguire, CFO
 Ivonne Cantu, Investor Relations

 Deutsche Numis (Broker and NOMAD)              Tel:  020 7260 1000
 Freddie Barnfield, Duncan Monteith, Sher Shah
 MHP                                            Tel:  020 3128 8100
 Katie Hunt, Reg Hoare, Veronica Farah          benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)

About Benchmark

Benchmark's mission is to enable aquaculture producers to improve their
sustainability and profitability. We bring together biology and technology, to
develop innovative products which improve yield, quality and animal health and
welfare for our customers. We do this by improving the genetic make-up, health
and nutrition of their stock - from broodstock and hatchery through to nursery
and grow out. Benchmark has a broad portfolio of products and solutions,
including salmon eggs, live feed (Artemia), diets and probiotics and sea lice
treatments. Find out more at www.benchmarkplc.com
(http://www.benchmarkplc.com)

 

 

Chairman's Statement

 

A year of delivery

2023 marks the third consecutive year of financial and strategic delivery
following the Group restructuring and the appointment of a new management team
in 2020. The new financial discipline and commercial focus implemented by our
CEO and CFO are now well embedded in the Group and, together with our ongoing
organisational change programme, are driving continued growth and strategic
progress. Since 2020 Benchmark's revenue from continuing operations has grown
from £105.4m (after adjusting for £0.2m revenue from the divested tilapia
business) to £169m and Adjusted EBITDA has increased from £15.5m (after
adjusting for loss of £1.1m from the divested tilapia business) to £35.5m,
turning operating cashflow positive. In the same period, operating loss has
reduced from £9.6m (after adjusting for loss of £1.2m from the divested
tilapia business) to £5.3m, and total loss for the year has reduced from
£31.9m to £21.6m.

 

We have a strong business with a capable organisation which is capitalising on
the attractive megatrends in our industry, and which has proven its agility to
adapt to the cyclicality in our end markets, taking every opportunity to
further consolidate our leading market position.

 

The structural growth drivers in our industry are increasingly compelling.
Aquaculture plays a crucial role in meeting the demand for seafood and
represents a growing proportion of seafood consumption.

 

In addition, there are a number of exciting trends gaining momentum which are
further driving the demand for innovative biotechnology solutions which are
our focus. For instance, the increasing adoption of certification standards;
the adoption of technological advancements, from automation to genetic
improvements; the emergence of alternative feeds; and the increased use of
data driven, AI enabled decision making are all aligned with and support
Benchmark's future growth.

 

Organisational transformation

We continued our strategic journey to integrate and streamline our
organisation in order to realise synergies, reduce costs and enhance our
customer value proposition. This is an effort that commenced three years ago
and crystallised this year with the integration of our Health, Genetics and
Advanced Nutrition salmon and shrimp offerings by species in order to drive
greater synergies into those end markets.

 

This means we can now fully leverage our customer relationships and commercial
footprint to cross-sell our offerings and develop new products and solutions.
Our salmon and shrimp activities are now respectively led by Geir Olav
Melingen and Patrick Waty, both strong commercial leaders, who also continue
to be business area heads for Genetics and Advanced Nutrition. As a result of
the change we were able to streamline the teams with immediate cost savings.

 

Listing venue and share price performance

It is evident to the Board that our share price does not reflect the
fundamental value of the business, its growing track record, or unique
strategic positioning and attractive prospects. In an effort to address this
longstanding issue, the Board decided to pursue a listing in Oslo, the leading
seafood market in order to attract specialist investors and over time attain a
fair valuation for our shares. An initial listing on Euronext Growth Oslo
announced in November 2022 represented a first step towards this goal, to be
followed by an uplisting to the Oslo Børs, subject to shareholder approval.

 

In 2023, we conducted a consultation with shareholders regarding an uplisting
to the Oslo Børs and simultaneous delisting from AIM. However, we concluded
from these discussions that it was necessary to maintain listings on both
Euronext Growth Oslo and on AIM for the foreseeable future and keep an
uplisting under review as part of the Group's ongoing strategy to deliver
shareholder value.

 

Board changes

During the year we made changes to the Board that increased shareholder
representation, improved the gender

balance, and addressed the normal Board rotation cycle.

 

In December we appointed Laura Lavers as Non-Executive Director. Laura is an
experienced investment professional with two decades of experience and acts as
shareholder representative for JNE Partners, a significant shareholder in the
Company. In April, we announced the appointment of Torgeir Svae as Non-
Executive Director with Atle Eide stepping down at the same time. Torgeir is
an Investment Director at Kverva AS, one of the Company's main shareholders,
and acts as their shareholder representative.

 

Following the appointments of Mrs Lavers and Mr Svae, alongside our
independent directors, we have three Non-Executive Directors representing our
three main shareholders who collectively hold 71% of the Company's shares.

 

As a step to enhance Board diversity in the normal rotation of Directors, on
30 June we appointed Marie Danielsson as Non-Executive Director and Chair of
the Audit Committee succeeding Kevin Quinn who joined the Board in 2016.

 

In December 2023, Susan Searle, the Company's most tenured Board member, will
conclude her service on the Board. The Board wishes to express its heartfelt
gratitude for her exceptional contributions and dedicated work over the past
decade.

 

Sustainability

Sustainability is at the core of our mission and our sustainability strategy
runs across all our business and extends to our supply chain; it guides our
decision-making and investment strategy. Our sustainability report including
in the group's Annual Report for the year ended 30 September 2023 sets out the
initiatives the progress made during the year in our three Sustainability
pillars: Environment, Animal Welfare and People and Communities. We set
priorities for our three pillars in alignment with a materiality assessment
carried out annually which reflects key areas of impact for the business and
our stakeholders. This year areas of focus included certification of our
operations, sustainability of our supply chain, and enhanced climate risk
assessment reporting.

 

Through enhanced disclosure and policies we were pleased to achieve an
improvement in our MSCI ESG ratings to AA.

 

We have an ambitious commitment to energy transition. In 2023, we made
substantial progress towards our Net Zero goals with the installation of solar
panels in our facility in Thailand which represents the majority of our GHG
emissions. The new solar panels will be operational in Q1 FY24.

 

Our People

Benchmark is driven by a group of highly talented and motivated people at all
levels around the world, and I thank them all on the Board's behalf for their
contribution this year. We continued to invest in making Benchmark a great
place to work through an ambitious engagement programme, new learning and
development resources, and regular, open communication with the management
team. For a third consecutive year we obtained excellent engagement scores in
our employee survey, well above the industry norm.

 

Looking forward

Our organisation is stronger than ever and, with market leading positions in
our three business areas, I am confident that we will continue to build on our
record of consistent delivery despite short term headwinds in some of our
markets. Our focus continues to be on creating shareholder value by building a
sustainably profitable, cash generative business positioned to capitalise on
the opportunity to deliver healthy, nutritious, sustainable food for our
future generations.

 

Peter George

Chairman

 

 

 

Chief Executive Officer's Review

 

Delivery and strategic progress

 

Third consecutive year of financial and strategic delivery

I am pleased to report a third consecutive year of financial delivery and
strategic progress at Benchmark. The change programme which we embarked on
three years ago and which is ongoing has transformed Benchmark into a robust
and commercial organisation with leading market positions focused on
delivering growth and shareholder value.

 

Supported by industry megatrends and growing interest in sustainability,
farming efficiency and animal welfare, Benchmark is uniquely positioned in the
aquaculture industry. With a clear focus on three business areas - Genetics,
Advanced Nutrition and Health we deliver specialised, mission critical
solutions that address the most important challenges facing the aquaculture
industry today. This creates excellent opportunities and prospects ahead for
Benchmark.

 

FY23 Overview

We delivered good growth in revenue and Adjusted EBITDA despite challenging
conditions in the global shrimp markets. This demonstrates the strength of our
business and the agility of our organisation to adapt - mitigating the impact
of a soft market and taking advantage of commercial opportunities to further
consolidate our leading market position. We continued to build on our
established track record of growth and improved profitability with revenues
increasing by 7%, and Adjusted EBITDA from continuing operations excluding
fair value movements from biological assets by 15%. Operating loss for the
year reduced by 15% from the previous year, and total loss for the year
reduced 29%. Since the end of FY20 when we completed the Group restructuring,
revenues and Adjusted EBITDA from continuing operations have increased by 61%
and 128%, respectively after adjusting for the divested tilapia business. In
the same period, operating loss reduced by 45% and total loss for the year
reduced by 32%.

 

Good performance in our core established business

Our three business areas reported good contribution and progress. Advanced
Nutrition showed the strength of an excellent organisation and was able to
land a good year despite weak shrimp markets which resulted in a drop in
demand for our products in key markets. Genetics increased revenues by 14%
driven by its core established business with record salmon egg sales from its
three facilities in Iceland, Salten and Chile, and continued to invest in its
growth vectors. Health reported 27% revenue growth. With leading market
positions, good commercial momentum, and growth in our underlying markets we
expect further organic growth in our core areas.

 

Innovation capability coupled with deep market insight sets us apart. During
the year we strengthened our Genetics R&D team with a focus on
reproductive technologies aiming to bring new breakthroughs in sterility and
gene editing to the market in the coming years. In Advanced Nutrition we
launched our first AI-powered artemia counting tool SnappArt, an example of
how we incorporate state of the art technology into our product offering.

 

Growth vectors

In addition to the growth potential across our established core business, we
have three significant growth vectors which represent strategic priorities for
the Group:

·    the commercial expansion of our salmon genetics into the Chilean
market;

·    the commercialisation of our shrimp genetics products; and

·    the development of a new business model and operating platform for
Ectosan® Vet and CleanTreat®.

 

During the year we devoted considerable effort and resources to ensure that we
have a compelling customer proposition and the right infrastructure and cost
base in each of our growth vectors to deliver adequate returns.

 

Chile is the second largest salmon producing country in the world and a
natural new market for our salmon

genetics business. Barriers to entry in genetics are high and it is by
leveraging our world class genetics expertise to develop a pure Chilean strain
and our extensive operational capabilities that we have a competitive product
in the market which is reliable, biosecure and high performing. Results from
our first full production cycle demonstrate this, translating into new
customer wins and a growing pipeline of orders supported by an intense
commercial effort from our local and global team.

 

We see significant potential in shrimp genetics as a driver of growth and
sustainability in shrimp production; indeed, this is an area where Benchmark
has world class capabilities and expertise. We launched our first commercial
shrimp genetics products in 2022 exporting breeders from our production
facility in Florida to multiple markets in Asia. Based on feedback from the
first commercial phase, in FY23 we decided to develop a new range of products
addressing a need in the market for growth and balanced strains in addition to
resistance, as well as a need for locally adapted strains tailored to
variations in customer needs across countries. We undertook trials to enable
product testing in local conditions and our new product development is well
progressed. We also took the decision to exit our JV multiplication centre in
Thailand and plan to develop alternative market routes for our shrimp genetics
through partnerships with other industry players, leveraging our extensive
network and established relationships.  In order to leverage our leading
market position and commercial network in the shrimp market through Advanced
Nutrition, we combined our shrimp activities across Genetics and Advanced
Nutrition under the leadership of Patrick Waty, our Head of Advanced
Nutrition.

 

Our sea lice solution Ectosan® Vet and CleanTreat® has proven to be highly
efficacious, protective of animal welfare and the environment, and represents
a key growth vector for Benchmark. During the year there was increased
adoption of our sea lice solution by small and large producers along the
entire Norwegian coastline. Full market penetration, however, relies on the
development of a new business model and configuration aligned to our
customers' infrastructure. During the year we signed an agreement with a
specialist wellboat equipment provider, MMC, and ship designer, SALT, to
integrate CleanTreat® systems into new wellboats.

 

This also opens up opportunities for retro-fits or installations on platforms
other than the current PSV (platform supply vessel) setup. The implementation
of the new business model will allow us to streamline the organisation and
reduce capital intensity. Part of these actions are reviewing different
options to optimise operations and cash flow on our journey towards fully
integrated customer-owned systems, including taking down the exposure to the
capital intensive setup we currently hold with two PSV's.

 

Strategic Action

We continue our efforts to integrate and streamline the Group - making sure we
have an organisation that is as optimal as possible from an operational and
commercial point of view. To this end we executed an important alignment in
the year bringing together our salmon activities under the leadership of our
Head of Genetics and our shrimp activities under the leadership of our Head of
Advanced Nutrition. This customer-centric will enable us to increase our
commercial impact with a combined offering and customer network, leveraging
resources and knowledge and further strengthening our market leading position.

 

Our overarching aim to achieve profitability and sustainable cash generation
led to the decision to exit from our tilapia breeding operation while
maintaining our exposure to this species through our Genetic Services
business. Having developed top performing genetics and an efficient operation
and supply chain, the slow industrialisation and adoption of tilapia genetics
in the industry meant that we did not see a path to adequate returns in the
short and medium term. We were pleased to have exited the business through a
management buyout and we continue to work with the new owners providing
support for the breeding programme through our Genetics Services activities.

 

Our culture and our people

Benchmark's purpose driven team and culture is our most important asset. Our
values underpin the way we conduct our business and create a collaborative,
innovative and commercial organisation which I am very proud of. We take
employee well-being and engagement seriously and create regular opportunities
to facilitate dialogue.  These are an important pillar in making Benchmark a
'Great Place to Work'.

 

Looking forward - Outlook

We have had a good start to the year and there is good momentum in the
business. We have good visibility of sales in Genetics at normalised levels
following the supply shortage experienced Q1 FY23. In Advanced Nutrition we
are seeing early signs of recovery in the shrimp markets which we expect will
contribute positively from Q2 FY24 onwards. Our CleanTreat® units are
currently operating at a good capacity utilisation and we expect this to be
reflected in Q1 FY24. We expect normal seasonality with low treatment volumes
in the second half. We are considering actions to optimise our operations and
cashflow during the transition to an integrated customer solution. The
continued integration and streamlining of the Group will enable us to further
leverage the Group capabilities and drive efficiencies contributing to a
positive outlook for the year ahead.

 

Looking into the future, we are uniquely positioned in an industry that is
structurally growing. With a clear strategy addressing the main aquaculture
species, we have significant opportunity to deliver growth and shareholder
returns. We will continue the development of the Group and ongoing
consideration of our strategy to realise the value inherent in our business
for the benefit of all our stakeholders.

 

 

Trond Williksen

Chief Executive Officer

 

 

Financial Review

 

Strong and positive performance in the year

 

We continued to develop a business structured for growth and resilience. FY23
has been a year of significant progress in which we have delivered sales
growth in both Genetics and Health, our two salmon focussed business areas.
Additionally, in Advanced Nutrition, we have been able to continue to make
progress even despite difficult economic conditions in which the market
contracted. Our continued focus on cost and cash conservation has proven key
to our progress and we ended the year with healthy cash, net debt and
available liquidity position. We anticipate that the shrimp markets will
improve somewhat in FY24 and our shrimp focussed businesses are poised to
benefit. Salmon continues to be a very solid market for the Group allowing us
to continue to progress the business in line with our strategic objective to
be the preferred supplier of salmon eggs in all key markets.

 

Overview of reported financial results During 2023, the Group's focus was on
continuing to strengthen the business and deliver good commercial results and
advancing its strategic priorities with the aim to be cash generative.

 

Advanced Nutrition continued to deliver strong results even as they faced
headwinds in the shrimp markets demonstrating good resilience within the
business area. Genetics had a good year with strong sales and solid results,
and with Ectosan® Vet and CleanTreat® sales gaining more traction in Health
this resulted in an increase in Group revenue of 7% to £169.5m in the year
(2022 restated: £157.7m). This increase in sales meant that gross profit
increased to £86.8m (2022 restated: £83.9m). Gross margin was slightly down
at 51% (2022 restated: 53%). Using the same foreign exchange rates experienced
in 2022 (constant currency⁵) revenue increased by 7%.

 

                                                                2022

 As Reported (£m unless otherwise stated)               2023    restated*   % AER   % CER(**)
 Revenue from continuing operations                     169.5   157.7       7%      7%
 Operating loss from continuing operations              (5.3)   (6.2)       15%     22%
 Loss before tax from continuing operations             (12.7)  (21.4)      41%     44%
 Loss for the period including discontinued operations  (21.6)  (30.5)      29%     31%
 Basic loss per share (p)                               (3.16)  (4.60)      31%     -

*2022 numbers have been restated to reflect changes to the ongoing continuing
business following the disposal of the tilapia business during the year.

** Constant exchange rate (CER) is the change year on year translating current
figures using last year's foreign exchange rates.

 

                                                                               2023    2022          % AER  % CER(**)

 Adjusted Measures (£m unless otherwise stated)                                        restated(*)
 Gross profit from continuing operations                                       86.8    83.9          3%     4%
 Gross profit %                                                                51%     53%           -      -
 Gross profit from continuing operations exc movements in fair value of        86.9    82.3          5%     6%
 biological assets
 Gross profit %                                                                51%     52%           -      -
 Adjusted EBITDA(1) from continuing operations                                 35.5    32.6          9%     11%
 Adjusted EBITDA(1) margin %                                                   21%     21%           -      -
 Adjusted EBITDA(1) from continuing operations exc movements in fair value of  35.6    31.0          15%    16%
 biological assets
 Adjusted EBITDA(1) exc fair value movements margin %                          21%     20%           -      -
 Adjusted Operating Profit(2) from continuing operations                       14.6    10.7          36%    41%
 Net debt(3)                                                                   (65.5)  (73.7)        11%    -

*2022 numbers have been restated to reflect changes to the ongoing continuing
business following the disposal of the tilapia business during the year.

** Constant exchange rate (CER) is the change year on year translating current
figures using last year's foreign exchange rates.

1     Adjusted EBITDA is EBITDA (earnings before interest, tax,
depreciation and amortisation and impairment) before exceptional and
acquisition-related items.

2     Adjusted Operating Profit is operating loss before exceptional and
acquisition-related items and amortisation of intangible assets excluding
development costs.

3     Net debt is cash and cash equivalents less loans, borrowings and
lease obligations.

 

Business area performance

 

We continued to manage costs across the Group very closely. Operating costs
from the continuing business increased by 2% to £45.2m (2022 restated:
£44.1m) with increased costs in Genetics and Advanced Nutrition driven in the
main by inflation offset by cost cuts in Health. Expensed R&D from
continuing operations decreased by 9% to £6.1m (2022 restated: £6.6m).

 

Adjusted EBITDA from continued operations increased by 9% to £35.5m (2022
restated: £32.6m) driven by increased performance in Health which offset
Genetics where we had significant investment in shrimp genetics as well as
lower fair value uplift and Advanced Nutrition.

 

Adjusted measures

We continue to use adjusted results as our primary measures of financial
performance. We believe that these adjusted measures enable a better
evaluation of our underlying performance. This is how the Board monitors the
progress of the Group.

 

We use growth at constant exchange rate metrics when considering our
performance, in which currency balances are retranslated at the same exchange
rates in use for the prior year to illustrate growth on a currency
like-for-like basis.

 

In line with many of our peers in the sector, we highlight expensed R&D on
the face of the income statement separate from operating expenses.
Furthermore, we report earnings before interest, tax, depreciation and
amortisation ("EBITDA") and EBITDA before exceptional and acquisition- related
items ("Adjusted EBITDA"). The activities of the Group's equity accounted
investees are closely aligned with the Group's principal activities, as these
arrangements were set up to exploit opportunities from the Intellectual
Property ("IP") held within the Group. As a result, to ensure that adjusted
performance measures are more meaningful, the Group's share of the results of
these entities is included within Adjusted EBITDA. We also report this
adjusted measure after depreciation and amortisation of capitalised
development costs ("Adjusted Operating Profit") as the Board considers this
reflects the result after taking account of the utilisation of the recently
expanded production capacity.

 

In addition, in line with the Salmon industry, we also report Gross profit and
AEBITDA excluding fair value uplift under IAS 41. Available liquidity, being
cash and undrawn facilities, is an important metric for management of the
business as it gives a measure of the available liquid funds and is also a key
financial covenant in the Group's main debt facilities.

 

Genetics

Despite forex headwinds impacting both NOK and ISK, Genetics delivered good
growth in revenue driven by sales of salmon eggs where volumes increased by
15% to 335 million eggs. Total revenues from continuing operations of £65.5m
(2022 restated: £57.4m) were up 14%, 20% in constant currency.

 

Egg sales in our biggest market, Norway, increased by 17% during the year,
with most of the demand being met by higher production volumes from our Salten
facility. We also saw increased sales to almost all other territories in the
year, resulting in an increase in revenue from salmon eggs of 19% to £45.6m
(2022: £38.3m).

 

In non-product-based revenue streams, revenues from harvested fish were aided
by increased salmon prices resulting in harvest income in the year of £11.1m
(2022: £8.5m). Royalties earned from use of our genetic IP fell in the year,
with sales down to £0.5m (2022: £0.8m). No further revenues are expected
from this revenue stream as the expected unwind of contracts is now complete.
Genetic Services delivered slightly lower revenues of £1.2m in the year
(2022: £1.3m), but revenues from this income stream are expected to increase
in future years as we build on the strength and depth of our recently expanded
genetics team and our IP in the business. Revenues from other products
totalled £7.4m (2022: £9.1m).

 

Gross profit from continuing operations reduced by 7% in 2023 to £30.6m (2022
restated: £32.8m) and gross margin fell to 47% (2022 restated: 57%). The
reduction in gross margin was due to a number of factors. We experienced
higher third-party production costs on our broodstock licence, inflation in
our own costs and non-capitalisation of shrimp development costs in the year
(£1.0m capitalised in 2022). Additionally, the fair value movement of bio
assets fell to a reduction of £0.1m in 2023 which is a combination of a
slowing in the growth of our biomass and lower eggs being incubated at the end
of the year, compared to an increase of £1.6m in 2022, as the overall value
of biological assets fell versus prior year.

 

The previously announced strategic review of our tilapia business was
completed in Q4 and as a result we sold the tilapia assets in a management
buy-out. Our Genetics Services team will continue to support the ongoing
development of the tilapia breeding programme on an arms-length basis. The
tilapia operation had revenues of £0.3m in the year (2022:£0.6m) and an
AEBITDA loss of £1.3m (2022: loss of £1.4m). We also booked exceptional
costs of £3.9m in the year (2022: £nil) relating to termination of the
business.

 

Our work to refine the shrimp genetics product line is ongoing and we have
lower commercial activities during the year. Prevailing conditions in the
shrimp markets have also affected this area of our business. Shrimp sales in
the year of £1.2m were behind last year (2022: £2.0m) and Adjusted EBITDA
losses of £3.6m were £2.0m worse than prior year, £1.0m of which, as noted
above, was due to capitalisation of development costs for the shrimp nucleus
in 2022 before it launched commercially.

 

R&D spend was £0.6m lower in the year (2023: £3.7m, 2022: £4.3m) and
operating costs were higher by £0.6m (2023: £11.2m, 2022: £ 10.6m) as the
business grew. R&D reduced due to good cost optimisation in this area.
R&D activities in this business area are focused on developing the traits
of growth, disease resistance and sea lice resistance by selecting the best
performing animals from each generation supported by cutting edge genetic
technologies. The search for markers for new traits that can be included in
the breeding programme continues.

 

The share of profits/losses from the equity accounted investees relates to the
joint venture with Salmar Genetics AS where we recorded a share of profit of
£0.03m in 2023 (2022: share of loss of £0.5m), and a share of losses of
£0.2m at Benchmark Genetics Thailand (2022: share of losses of £0.1m). Post
year- end, as part of consolidating the shrimp genetics business under Patrick
Waty, Genetics has continued to establish its facilities in Chile and with
overall AEBITDA losses of £2.9m and £0.1m invested in capex in these
facilities in 2023 (2022: £3.4m and 0.6mm). These facilities have potential
production capacity of 50 million eggs and is currently utilising capacity of
around 30 million eggs. During the year we sold 7 million eggs.

 

All these factors contributed to increased AEBITDA from continuing business of
£15.7m (2022 restated: £17.4m) and AEBITDA margin of 24% (2022 restated:
30%). AEBITDA from continuing business excluding fair value was the same as
prior year at £15.8m (2022 restated: £15.8m) with an AEBITDA margin of 24%
(2022 restated: 28%).

 

Advanced Nutrition

Throughout 2023, Advanced Nutrition delivered a resilient performance driven
by continued commercial and customer focus. Advanced Nutrition had a good
start to the year but at that stage we could already see weakening within the
shrimp markets. This continued throughout the year but we have delivered
strong results despite the market trends. Revenues in Advanced Nutrition
decreased by only 2% in the year (7% at CER) as our strong commercial focus
has allowed us to continue to strengthen our position and take increased
market share even as the market has softened.

 

In 2023 and 2022, 73% of our revenues derived from shrimp, with the balance
27% of derived from the Mediterranean sea bass and sea bream sector. By
product area, artemia revenue were £36.7m (2022: £37.4m) followed by diets
£32.6m (2022: £35.3m). health which covers our probiotic and environmental
pond management portfolio grew revenues by 13.6% to £9.2m (2022: £8.1m).

 

Gross profit of £43.8m (2022: £42.6m) showed an increase of 3% at AER but a
reduction of 1% at CER after the effect of the foreign exchange tailwinds.
However, good cost control and reducing logistics costs during the year along
with lower cost of goods for our Artemia products helped support the
resilience of the business. As a result we saw an increase in gross profit
margin up from 53% to 56%. This increase in gross profit was offset in part by
an increase in operating costs as we saw the full year effect of the
investment made in the business during 2022. There continued to be strong cost
control and where appropriate staff reductions throughout this year in light
of difficult market conditions. Operating costs grew to £23.4m (2022:
£21.5m). This led to Advanced Nutrition reporting AEBITDA of £18.4m (2022:
£19.0m) and a slight decrease in AEBITDA margin from 24% to 23%.

 

Within this business area, an important barrier to entry is the access to GSL
Artemia where we, through our relationship with the Great Salt Lakes
Cooperative have access to 44% of the annual harvest of Artemia from the Great
Salt Lakes.

 

Health

Health reported revenue of £25.5m (2022: £20.1m) largely reflecting
increased market traction for Ectosan®Vet and CleanTreat® which represented
of £17.2m of revenue (2022: £14.8m) of which £4.8m relates to revenue for
vessel-related costs (2022: £2.5m). Additionally, it was a good year for our
other sea lice treatment, Salmosan® Vet, which showed a resurgence of demand
in the year driven mainly by label changes which allow longer use in certain
territories and delivered revenue of £8.3m (2022: £5.4m).

 

Gross profit increased by £3.8m to £12.3m, driven by the increased sales
from of Ectosan®Vet and CleanTreat® combined with increased margins from
Salmosan® Vet. Gross margin increased to 48% (2022: 43%), due to increased
Ectosan®Vet and CleanTreat® sales.

 

During the year, the focus of this business area has been to drive demand for
Ectosan®Vet and CleanTreat® in Norway and also to lay the ground work for
moving the Cleantreat® treatments away from Benchmark leased and controlled
vessels, onto customer owned platforms. This will reduce the capital intensive
nature of the solution and ultimately reduce costs for the customer, making it
a more attractive solution to use for the treatment of sea lice. To date
capacity utilisation on the Cleantreat® vessels varied with treatment
seasonality which translated into utilisation of c.50% in each vessel during
FY23. We are reviewing different options to manage capacity and optimise
operations and cash flow as we transition towards fully integrated customer
owned systems on wellboats. This may include reducing the exposure to the
capital intensive setup we currently hold with two PSV's. With cash and cost
control being a very key focus for this business area, operating costs
decreased to £7.3m (2022: £8.1m) and research and development fell to £0.3m
(2022: £0.4m). Adjusted EBITDA for the business area was £4.8m (2022:
£0.1m). AEBITDA margin was 19% for 2023 (2022: 1%).

 

Within Health and Genetics, given the commonality of customers we adopted a
single sales and marketing team approach which has been in place during the
financial year. To further drive these efforts, Health and Genetics were
brought under common operational leadership during the year under Geir Olav
Melingen. We will continue to report these as separate segments to aid in
transparency of results.

 

Cost Inflation

As noted earlier, cost control remains of significant importance in Benchmark
and in the current inflationary environment becomes even more so. During the
year, we saw higher cost inflation in a number of areas, the most significant
of which related to salaries. Within Health we were able to mitigate this by
reducing the overall number of headcount and limiting discretionary spend.
Within Genetics and Advanced Nutrition, we have, within the constraints of
existing contracts, tried to increase prices and also limit discretionary
spend to mitigate. Within Advanced Nutrition, a number of roles were also
reorganised to make the operation leaner to best fit the current market
conditions.

 

Exceptional items

Items that are material because of their nature whose significance is
sufficient to warrant separate disclosure and identification within the
consolidated financial statements are referred to as exceptional items. The
separate reporting of exceptional items helps to provide an understanding of
the Group's underlying performance.

 

                                         2023   2022
                                         £mil   £mil
 Aborted acquisition related items       0.6    -
 Exceptional restructuring costs         0.9    1.2
 Costs associated with the Oslo listing  2.6    -
 Cost in relation to disposals           (0.2)  (1.2)
 Total exceptional items                 3.9    (nil)

The above table excludes £3.9m of exceptionals included within discontinued
operations as mentioned earlier.

 

Exceptional expenses in 2023 were mainly driven by legal and professional
costs in relation to the dual listing on the Oslo exchange of and
consideration of uplisting to the Oslo Børs of £2.6m. Within Health and
Advanced Nutrition some restructuring occurred during the year, in Health to
move towards the integration of the operational leadership and within Advanced
Nutrition to adapt to the changes in the markets. This resulted in costs of
£0.9m (2022: £1.2m). The costs were offset by a credit of £0.2m (2022:
£1.2m) relating to additional contingent consideration received in the period
following the disposal of Improve International on 23 June 2020, actually cash
received was £1.25m related to this divestment.

 

Depreciation, amortisation and impairments

Depreciation and impairment of tangible assets including discontinued
operations and right of use assets was £18.7m (2022 restated: £19.9m). In
total, depreciation and impairment charges on right of use assets under IFRS
16 was £10.3m (2022 restated: £11.3m). The charge within discontinued
operations included above was £0.3m (2022: £0.2m). Amortisation and
impairment of intangible assets totalled £18.5m (2022: £19.2m). This
includes an impairment charge of £0.5m related to some intellectual property
within Health which is deemed no longer to be of value. We expect the
amortisation charge to start reducing from FY25 as some of the Advanced
Nutrition (INVE) assets will be fully amortised then.

 

Research and development

                                    Expensed                                                         Total expensed and capitalised
                                    2023                                                             2023

 £m                                 Continuing business   As % of sales   2022       As % of sales   Continuing business   As % of sales   2022       As % of sales

                                                                          restated                                                         restated
 Expensed R&D by business area
 Genetics                           3.7                   6%              4.3        7%              3.7                   6%              5.2        9%
 Advanced Nutrition                 2.1                   3%              2.0        2%              2.1                   3%              2.1        3%
 Health                             0.3                   1%              0.4        2%              0.9                   4%              1.0        5%
 Total research and development     6.1                   4%              6.7        4%              6.7                   4%              8.3        5%

 

Expensed R&D activities decreased in the year by £0.5m with Genetics
having good cost optimisation in this area while continuing to focus on
improvements in the breeding nucleus. Health spending remained low due to
their significantly reduced R&D programmes. Genetics' research is focused
around continually developing new disease and parasitic resistant traits as
well as growth traits which we can breed into our products. Advanced
Nutrition's focus is on expanding our product portfolio and driving growth
through product improvements.

 

Other operating costs

                                                                     As % of sales  2022       As % of sales

 £m                                                           2023                  restated
 Operating Expenses for continuing business by Business Area
 Genetics                                                     11.2   17%            10.6       18%
 Advanced Nutrition                                           23.4   30%            21.5       27%
 Health                                                       7.3    29%            8.1        40%
 Corporate (net)                                              3.3                   3.9
 Total operating expenses                                     45.2   27%            44.1       28%

 

Other operating costs within the continuing business increased from £44.1m in
2022 (restated) to £45.2m in 2023. The modest increase in costs reflects the
impact of cost inflation being mitigated by good cost control and limiting
discretionary spend.

 

Discontinued Operations

During the year we initiated a strategic review of our tilapia operations with
a view to understanding the timeline to cash generation within the area of our
Genetics business. As a consequence of this review we divested the business
via a management buy-out in the fourth quarter of the financial year.

 

Net finance costs

 

                                                  2022

 £m                                        2023   restated
 Interest Income                           (0.6)  (0.3)
 Foreign Exchange gains                    (0.3)  (2.8)
 Interest on bond and bank debt            8.4    6.2
 Amortisation of deferred financing fees   0.5    1.9
 Penalty for early settlement of the bond  -      1.6
 Movements in hedging instruments          (2.2)  7.0
 Finance lease interest                    1.6    1.6
 Total net finance expenses                7.4    15.2

 

The Group incurred net finance costs of £7.4m during the year (2022 restated:
£15.2m). Included within this was interest charged on the Group's
interest-bearing debt facilities of £8.4m (2022: £6.2m), the higher interest
cost was due to higher utilisation of the RCF facility during the year and
also higher interest coupon on the bond. In addition, a further £0.5m was
charged on amortisation of the deferred finance costs (2022: £1.9m). Net
foreign exchange gains of £0.3m (2022 restated: net gain of £2.8m) arose due
to the movement in exchange rates on intercompany loans and external debt.
Movements on the hedging instruments associated with the Group's NOK bond debt
resulted in gains of £2.2m (2022: loss of £7.0m).

 

Statutory loss before tax

The loss before tax from continuing operations for the year at £12.7m is
lower than the prior year (2022 restated: loss of £21.4m). This was a result
of the positive trading result offset by higher exceptional items and lower
finance costs due to changes in fair value of in-effective portion of cash
flow hedges slightly offset by unfavourable foreign exchange movements.

 

Taxation

There was a tax charge on the loss for the year of £3.4m (2022: £7.3m),
mainly due to overseas tax charges in Genetics and Advanced Nutrition in
territories where no loss relief is available, partially offset by deferred
tax credits on intangible assets mainly arising on consolidation from
acquisitions.

 

Other Comprehensive Income

In addition to the loss for the year of £21.6m, there was a significant
movement of £23.0m in OCI resulting from movements in the foreign exchange
and hedging reserves. The forex loss of £23.5m was driven by USD and NOK
impacting the retranslation of foreign currency denominated subsidiary balance
sheets into GBP offset by amounts designated as net investment hedges,
together with long term internal loans not expected to be repaid in the
foreseeable future which are treated like equity with the movements going
directly to reserves. These were offset by £0.5m credit into the hedge
reserve from hedge accounting on cashflow hedges.

 

Transfer and cancellation of share premium

During 2023, we obtained approval via the AGM to cancel part of the share
premium account and transfer it to retained earnings. This amounted to
£394.2m. This has allowed the business to increase its distributable reserves
and serves as a step towards the goal of being a cash generative group, able
to issue dividends in line with its dividend policy.

 

Reported loss for the year

The loss for the year from the continuing business was £16.1m (2022 restated:
loss of £28.7m). The total loss from continuing activities and discontinued
operations was £21.6m (2022: £30.5m).

 

Loss per share

Basic loss and diluted loss per share were both 3.16p (2022: loss per share
4.60p). The movement year on year is due to the movement in the result as well
as the increase in the weighted average number of shares in issue of 33.7m.

 

Dividends

No dividends have been paid or proposed in either 2023 or 2022 and the Board
is not recommending a final dividend in respect of the year ended 30 September
2023.

 

Biological assets

A feature of the Group's net assets is its investment in biological assets,
which under IAS 41 are stated at fair value. At 30 September 2023, the
carrying value of biological assets was £46.0m (2022: £46.7m). This decrease
is due principally to the reduction in eggs available for sale in FY24
compared to FY23, as demand for our eggs was higher at the start of FY23 while
there were supply issues in the market which did not affect Benchmark. This
has normalised during the year. The fair value movement on biological assets
included in cost of sales for the year was a reduction of £0.1m (2022: uplift
of £1.6m).

 

Intangibles

Additions to intangibles were £0.8m (2022: £1.9m) with the main area of
investment being capitalised development costs which in the year decreased by
£1.1m to £0.6m (2022: £1.7m). R&D costs related to products that are
close to commercial launch have to be capitalised when they meet the
requirements set out under IAS 38. In this financial year, the main
development project capitalised was Salmosan Vet (£0.6m).

 

Capital expenditure

During 2023, to manage cash, we curtailed the investment incurred and focussed
on purely business critical areas. The Group incurred tangible fixed asset
additions of £6.0m (2022: £10.8m) broken down as follows:

·    Health:                 £0.7m (2022: £2.6m)

·    Genetics:             £3.4m (2022: £5.6m)

·    Nutrition:            £1.9m (2022: £2.6m)

 

Within Health, there was an increase in the provision to demobilise the
Cleantreat® units from the current vessels of £0.4m and additional equipment
for the existing Cleantreat® units of £0.3m. Capex associated with our
Genetics business was £3.4m where we finished the building of new tanks at
Salten to support ramping up to the 150 million egg capacity at that facility
(£1.4m) and we continue to invest in our production footprint in Iceland and
Salten. 2023 saw minimal investment in our growth initiatives in Chile and
shrimp as we believe they have been sufficiently invested. In Advanced
Nutrition we continued to invest in the two manufacturing facilities to
support growth and operational efficiency.

 

Cashflow, liquidity and net debt

 

                                                                          2023    2022

 Movement in net debt                                                     £m      £m
 Net debt at 30 September 2022/2021                                       (73.7)  (80.9)
 Cash generated from operations excluding working capital and taxes paid  29.6    30.3
 Investment in working capital                                            (1.1)   (12.0)
 Capital expenditure                                                      (6.8)   (12.7)
 Other disposal activities                                                0.2     (0.2)
 Foreign exchange on cash and debt                                        4.3     10.5
 Interest and tax                                                         (17.1)  (17.0)
 Proceeds from previous year disposals of subsidiaries                    1.3     1.5
 Acquisition of subsidiaries net of cash/debt acquired                    (0.2)   -
 Investment in associates                                                 (0.6)   (0.4)
 Acquisition of non controlling interest                                  (8.0)   -
 Additions to/modifications of leases (IFRS 16)                           (3.7)   (11.5)
 Shares issued                                                            10.9    20.2
 Other non-cash movements                                                 (0.6)   (1.5)
 Net debt at 30 September 2023/2022                                       (65.5)  (73.7)

 

Cash flow

With improved trading in the business, we saw strong cash generated from
operations of £29.6m (2022: £30.3m). During 2023 with significant focus on
cash conservation, we restricted the investment in working capital to £1.1m
versus an outflow last year £12.0m. Interest and taxes were in line with last
year. Capital expenditure, both intangible and tangible, showed a significant
decrease of £5.9m to £6.8m (2022: £12.7m) as we continue to moderate our
capex.

 

Working capital

Working capital has reduced slightly in the period driven by a number of
factors. We can see the impact of foreign exchange on the balance sheet as
noted above in the other comprehensive income section and this impacted the
working capital balances at 30 September 2023, but our investment in working
capital was more moderate this year as can be seen in the cash flow.

 

We noted earlier the decrease in biological assets within the genetics areas.
Other Inventories fell in Advanced Nutrition as we had less GSL Artemia in
inventory than previous years.

 

In Health, we had transferred the CleanTreat® equipment into inventory in
2022 but we had lower levels of inventory of Salmosan® Vet than 2022.

 

Trade debtors and creditors, of course, increased as a result of increased
sales but trade debtors decreased as a percentage of sales from 20% to 16% in
the year. Trade payables were 20% higher than last year as expected from
higher level of costs both from activity levels and from cost inflation.

 

A significant amount of cash is tied up with the working capital of the group
and focus will continue to be on releasing that investment in the years to
come.

 

Refinancing and borrowing facilities

The Group has a senior unsecured green bond issue of NOK 750 million, with an
expected maturity date of 27 September 2025. The bond has a coupon of three
months NIBOR* + 6.5% p.a. with quarterly interest payments. The Group also had
a USD 15m revolving credit facility ("RCF") which was due to mature in
December 2022 and had £4m drawn at 30 September 2022. During the year, this
RCF was refinanced by a new £20m RCF on 21 November 2022 with a June 2025
maturity. The interest rate on the facility is between 2.5% and 3.25% above
compound interest rate depending on leverage. At 30 September 2023, there was
£7.75m drawn on this facility (2022: £4.0m).

 

There are other borrowing facilities held within Benchmark Genetics Salten AS
which were originally put in place to fund the building of the Salten salmon
eggs facility. On 1 November 2022 the term loan facility outstanding balance
and the overdraft facility provided by Nordea were refinanced into one
facility totalling NOK179.5m with a maturity date of January 2028. The margin
on the new facility is 2.5%. In addition, a working capital facility of NOK
20.0m (renewal annually in March) is in place for use solely by Benchmark
Genetics Salten AS. This facility is undrawn (2022: undrawn). Two additional
ten-year term loans of NOK 25,000,000 and NOK 30,000,000 respectively provided
by Innovasjon Norge in 2018. These loans currently have a flat interest rate
of 5.95% per annum.

 

Cash and total debt

 

Net debt

 £m                 2023    2022
 Cash               36.5    36.4
 NOK 750m bond      (57.6)  (62.0)
 Other borrowings   (24.5)  (21.8)
 Lease liabilities  (19.9)  (26.3)
 Net debt           (65.5)  (73.7)

 

The RCF combined with the year-end cash balance of £36.5m (2022: £36.4m)
means the Group had total liquidity of £48.8m (2022: £45.8m). This, while
utilising tight cost and cash control, is expected by the Directors to provide
the Group with sufficient liquidity to fund the investment and working capital
required to crystalise the growth opportunities which are part of the
strategic priorities of the Group and provide adequate headroom.

 

Equity raise and Oslo Euronext Growth Listing

In December 2022, £10.8m net proceeds were raised through a placing to
provide the Company with sufficient free float to establish a listing on Oslo
Euronext Growth. The listing was completed on 15 December 2022 and we have
remained dual listed since that time. During 2023, the Board considered an
uplisting to Oslo Børs but ultimately through shareholder consultation, the
decision was made to remain dual listed on Euronext Growth and AIM. The
proceeds of this equity raise facilitated us in having sufficient available
cash to purchase the minority interest in our Icelandic operation.

 

Covenants

Banking covenants for the NOK bond and RCF exist in relation to liquidity and
an 'equity ratio'. Liquidity, defined as 'freely available and unrestricted
cash and cash equivalents, including any undrawn amounts under the RCF', must
always exceed the minimum liquidity value, set at £10m. Available liquidity
at 30 September 2023 is £48.8m (2022: £45.8m). The equity ratio, defined as
'the ratio of Book Equity to Total Assets' must always exceed 40%. The equity
ratio at 30 September 2023 was 60% (2022: 61%). In addition, an equity to
asset ratio covenant exists for the Benchmark Genetics Salten AS debt with a
target threshold of 40%, this equity to asset ratio was 60.0% at 30 September
2023 (2022: 51.3%).

 

Acquisition of Iceland minority Interest

In December 2014 Benchmark acquired an 89.48% interest in Stofnfiskur,
subsequently rebranding it Benchmark Genetics Iceland. Since the acquisition,
the business has grown substantially, benefitting from Benchmark's leading
market position, investment and knowledge transfer within the Group. In
February 2023, we acquired the remaining 10.52% minority interest in Benchmark
Genetics Iceland for a consideration of €9m. This acquisition is
strategically important as Benchmark Genetics Iceland is core to the Company's
ability to supply highly specialist, biosecure salmon eggs year-round to
salmon producers in c.25 countries around the world. Benchmark Genetics
Iceland represents 50% of the Group's salmon egg capacity.

 

Going concern

As at 30 September 2023 the Group had net assets of £282.6m (2022: £323.3m),
including cash of £36.5m (2022: £36.4m) as set out in the Consolidated
Balance Sheet. The Group made a loss for the year of £21.6m (2022: £30.5m).
As at 30 September 2023 the Company had net assets of £363.2m (2022:
£346.6), including cash of £0.3m (2022: £3.2m) as set out on the Company
Balance Sheet. The Company made a loss for the year of £4.2m (2022: £16.5m).

 

As noted in the Strategic Report, the business has performed steadily during
the year, showing resilience to some tough market conditions towards the end
of the year. The Directors have reviewed forecasts and cash flow projections
for a period of at least 12 months including downside sensitivity assumptions
in relation to trading performance across the Group to assess the impact on
the Group's trading and cash flow forecasts and on the forecast compliance
with the covenants included within the Group's financing arrangements.

 

In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan® Vet and CleanTreat® offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduction in short-term treatment capacity. Key
downside sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and
removal of an additional financing opportunity within Genetics, along with
sensitivities on sales growth in revenues and pressure on pricing on CIS
artemia in Advanced Nutrition. Mitigating measures within the control of
management have been identified should they be required in response to these
sensitivities, including reductions in areas of discretionary spend, tight
control over new hires, deferral of capital projects and temporary hold on
R&D for non-imminent products.

 

The refinancing exercise which commenced in FY22 was completed at the start of
FY23, so that adequate finance facilities are in place, and with financial
instruments in place to fix interest rates and opportunities available to
mitigate globally high inflation rates, the Group continues to show resilience
against current global economic pressures. The Directors are therefore
confident that even under all of the above sensitivity analysis, the Group has
sufficient liquidity and resources throughout the period under review whilst
still maintaining adequate headroom against the borrowing covenants. They
therefore remain confident that the Group has adequate resources to continue
to meet its liabilities as and when they fall due within the period of 12
months from the date of approval of these financial statements. Based on their
assessment, the Directors believe it remains appropriate to prepare the
financial statements on a going concern basis.

 

 

Consolidated Income Statement

for the year ended 30 September 2023

 

                                                                                                                   2022

                                                                                                        2023       Restated*

                                                                                                        £000       £000
 Revenue                                                                                                169,476    157,707

 Cost of sales                                                                                          (82,726)   (73,777)
 Gross profit                                                                                           86,750     83,930
 Research and development costs                                                                         (6,069)    (6,634)
 Other operating costs                                                                                  (45,157)   (44,095)
 Share of (loss)/profit of equity-accounted investees, net of tax                                       (32)       (595)
 Adjusted EBITDA²                                                                                       35,492     32,606
 Exceptional - restructuring/acquisition and disposal related items  4                                  (3,904)    16
 EBITDA¹                                                                                                31,588     32,622
 Depreciation and impairment                                                                            (18,409)   (19,692)
 Amortisation and impairment                                                                            (18,495)   (19,161)
 Operating loss                                                                                         (5,316)    (6,231)
 Finance cost                                                        3                                  (15,048)   (19,893)
 Finance income                                                      3                                  7,670      4,741
 Loss before taxation                                                                                   (12,694)   (21,383)
 Tax on loss                                                                                            (3,365)    (7,268)
 Loss from continuing operations                                                                        (16,059)   (28,651)
 Discontinued operations
 Loss from discontinued operations, net of tax                       5                                  (5,505)    (1,800)
                                                                                                        (21,564)   (30,451)
 Loss for the year attributable to:
 - Owners of the parent                                                                                 (23,146)   (32,087)
 - Non-controlling interest                                                                             1,582      1,636
                                                                                                        (21,564)   (30,451)
 Earnings per share
 Basic loss per share (pence)                                        6                                  (3.16)     (4.60)
 Diluted loss per share (pence)                                      6                                  (3.16)     (4.60)
 Earnings per share - continuing operations
 Basic loss per share (pence)                                        6                                  (2.41)     (4.34)
 Diluted loss per share (pence)                                      6                                  (2.41)     (4.34)

                                                                                                        £000       £000
 Adjusted EBITDA from continuing operations                                                             35,492     32,606
 Adjusted EBITDA from discontinued operations                                                           (1,254)    (1,425)
 Total Adjusted EBITDA                                                                                  34,238     31,181

1.     EBITDA - earnings before interest, tax, depreciation, amortisation
and impairment.

2.     Adjusted EBITDA - EBITDA before exceptional and acquisition-related
items.

*     2022 numbers have been restated to reflect certain operations of the
Group that have been classified as discontinued operations during the year in
line with IFRS 5

 

 

Consolidated Statement of Comprehensive Income

for the year ended 30 September 2023

 

                                                                          2023      2022

                                                                          £000      £000
 Loss for the year                                                        (21,564)  (30,451)
 Other comprehensive income
 Items that are or may be reclassified subsequently to profit or loss
 Foreign exchange translation differences                                 (23,475)  47,606
 Cash flow hedges - changes in fair value                                 (2,123)   2,627
 Cash flow hedges - reclassified to profit or loss                        2,623     2,546
 Total comprehensive income for the period                                (44,539)  22,328
 Total comprehensive income for the period attributable to:
 - Owners of the parent                                                   (45,404)  20,326
 - Non-controlling interest                                               865       2,002
                                                                          (44,539)  22,328
 Total comprehensive income for the period attributable to owners of the
 parent:
 - Continuing operations                                                  (39,777)  21,509
 - Discontinued operations*                                               (5,627)   (1,183)
                                                                          (45,404)  20,326

*     Total comprehensive income for the period relating to discontinued
operations for FY23 includes the loss of £5,505,000 (2022: £1,800,000) and
foreign exchange loss of £122,000 (2022: gain of £617,000).

 

 

Consolidated Balance Sheet

as at 30 September 2023

 

                                                                                  2023       2022

 Notes                                                                            £000       £000
 Assets
 Property, plant and equipment                                     7              73,411     81,900
 Right-of-use assets                                               8              19,804     27,034
 Intangible assets                                                 9              206,077    245,264
 Equity-accounted investees                                                       3,558      3,113
 Other investments                                                                14         15
 Biological and agricultural assets                                11             18,406     20,878
 Non-current assets                                                               321,270    378,204
 Inventories                                                                      25,269     29,813
 Biological and agricultural assets                                11             27,586     25,780
 Trade and other receivables                                       10             59,795     56,377
 Cash and cash equivalents                                                        36,525     36,399
                                                                                  149,175    148,369
 Assets held for sale                                                             850        -
 Current assets                                                                   150,025    148,369
 Total assets                                                                     471,295    526,573
 Liabilities
 Trade and other payables                                          13             (47,329)   (44,324)
 Loans and borrowings                                              14             (20,045)   (17,091)
 Corporation tax liability                                                        (6,422)    (10,211)
 Provisions                                                                       (1,280)    (1,631)
 Current liabilities                                                              (75,076)   (73,257)
 Loans and borrowings                                              14             (81,954)   (93,045)
 Other payables                                                    13             (6,842)    (8,996)
 Deferred tax                                                                     (24,106)   (27,990)
 Provisions                                                                       (700)      -
 Non-current liabilities                                                          (113,602)  (130,031)
 Total liabilities                                                                (188,678)  (203,288)
 Net assets                                                                       282,617    323,285
 Issued capital and reserves attributable to owners of the parent
 Share capital                                                                    739        704
 Additional paid-in capital                                                       37,428     420,824
 Capital redemption reserve                                                       5          5
 Retained earnings                                                                183,489    (185,136)
 Hedging reserve                                                                  (203)      (703)
 Foreign exchange reserve                                                         54,947     77,705
 Equity attributable to owners of the parent                                      276,405    313,399
 Non-controlling interest                                                         6,212      9,886
 Total equity and reserves                                                        282,617    323,285

 

The financial statements were approved and authorised for issue by the Board
of Directors on 29 November 2023 and were signed on its behalf by:

 

Septima Maguire

Chief Financial Officer

 

Company number: 04115910

 

 

Consolidated Statement of Changes in Equity

for the year ended 30 September 2023

                                                     Share capital  Additional paid-in share capital  Other reserves  Hedging reserve  Retained earnings  Total attributable to equity holders of parent  Non-controlling interest  Total equity

                                                     £000           £000                              £000            £000             £000               £000                                            £000                      £000
 As at 1 October 2021                                670            400,682                           30,470          (5,876)          (154,231)          271,715                                         7,884                     279,599
 Comprehensive income for the year
 (Loss)/profit for the year                          -              -                                 -               -                (32,087)           (32,087)                                        1,636                     (30,451)
 Other comprehensive income                          -              -                                 47,240          5,173            -                  52,413                                          366                       52,779
 Total comprehensive income for the year             -              -                                 47,240          5,173            (32,087)           20,326                                          2,002                     22,328
 Contributions by and distributions to owners
 Share issue                                         34             20,704                            -               -                -                  20,738                                          -                         20,738
 Share issue costs recognised through equity         -              (562)                             -               -                -                  (562)                                           -                         (562)
 Share-based payment                                 -              -                                 -               -                1,182              1,182                                           -                         1,182
 Total contributions by and distributions to owners  34             20,142                            -               -                1,182              21,358                                          -                         21,358
 Changes in ownership
 Acquisition of NCI                                  -              -                                 -               -                -                  -                                               -                         -
 Total changes in ownership interests                -              -                                 -               -                -                  -                                               -                         -
 Total transactions with owners of the Company       34             20,142                            -               -                1,182              21,358                                          -                         21,358
 As at 30 September 2022                             704            420,824                           77,710          (703)            (185,136)          313,399                                         9,886                     323,285
 Comprehensive income for the year
 (Loss)/profit for the period                        -              -                                 -               -                (23,146)           (23,146)                                        1,582                     (21,564)
 Other comprehensive income                          -              -                                 (22,758)        500              -                  (22,258)                                        (717)                     (22,975)
 Total comprehensive income for the year             -              -                                 (22,758)        500              (23,146)           (45,404)                                        865                       (44,539)
 Contributions by and distributions to owners
 Share issue                                         35             12,985                            -               -                -                  13,020                                          -                         13,020
 Share issue costs recognised through equity         -              (2,146)                           -               -                -                  (2,146)                                         -                         (2,146)
 Cancellation of part of share premium account       -              (394,235)                         -               -                394,235            -                                               -                         -
 Share-based payment                                 -              -                                 -               -                1,006              1,006                                           -                         1,006
 Total contributions by and distributions to owners  35             (383,396)                         -               -                395,241            11,880                                          -                         11,880
 Changes in ownership
 Acquisition of NCI                                  -              -                                 -               -                (3,470)            (3,470)                                         (4,359)                   (8,009)
 Total changes in ownership interests                -              -                                 -               -                (3,470)            (3,470)                                         (4,359)                   (8,009)
 Total transactions with owners of the Company       35             (383,396)                         -               -                391,771            8,410                                           (4,539)                   (8,009)
 As at 30 September 2023                             739            37,428                            54,952          (203)            183,489            276,405                                         6,212                     282,617

 

 

 

Consolidated Statement of Cash Flows

for the year ended 30 September 2023

                                                                                             2023      2022

 Notes                                                                                       £000      £000
 Cash flows from operating activities
 Loss for the year                                                                           (21,564)  (30,451)
 Adjustments for:
 Depreciation and impairment of property, plant and equipment                                8,453     8,602
 Depreciation and impairment of right-of-use assets                                          10,260    11,293
 Other adjustments for non-cash items                                                        -         (276)
 Amortisation and impairment of intangible fixed assets                                      18,495    19,161
 Profit on sale of property, plant and equipment                                             (121)     (43)
 Loss on sale of discontinued operation                                                      3,774     -
 Finance income                                                                              (2,802)   (319)
 Finance costs                                                                               10,535    18,437
 Increase in fair value of contingent consideration receivable                               -         (1,203)
 Share of loss of equity-accounted investees, net of tax                                     32        595
 Foreign exchange gains                                                                      (1,814)   (3,985)
 Share-based payment expense                                                                 1,005     1,182
 Tax expense                                                                                 3,365     7,274
 Increase in trade and other receivables                                                     (6,570)   (8,511)
 Decrease/(increase) in inventories                                                          2,877     (5,406)
 Increase in biological and agricultural assets                                              (1,659)   (6,099)
 Increase in trade and other payables                                                        3,909     6,948
 Increase in provisions                                                                      386       1,058
                                                                                             28,561    18,257
 Income taxes paid                                                                           (8,556)   (7,447)
 Net cash flows generated from operating activities                                          20,005    10,810
 Investing activities
 Acquisition of subsidiaries                                                                 (48)      -
 Purchase of investments in associates                                                       (558)     (378)
 Receipts from disposal of subsidiaries                                                      1,250     1,544
 Purchases of property, plant and equipment                                                  (5,953)   (10,808)
 Purchase of intangibles                                                                     (196)     (205)
 Capitalised research and development costs                                                  (632)     (1,708)
 Proceeds from sale of fixed assets                                                          227       220
 Cash receipts from swap contracts                                                           11        -
 Interest received                                                                           627       119
 Net cash flows used in investing activities                                                 (5,272)   (11,216)
 Financing activities
 Proceeds of share issues                                                                    13,020    20,737
 Share-issue costs recognised through equity                                                 (2,146)   (562)
 Acquisition of minority interests in subsidiaries                                           (8,009)   -
 Proceeds from bank or other borrowings                                                      21,847    67,939
 Repayment of bank or other borrowings                                                       (18,470)  (74,874)
 Interest and finance charges paid                                                           (9,131)   (9,629)
 Repayments of lease liabilities                                                             (9,438)   (10,533)
 Net cash used in financing activities                                                       (12,327)  (6,922)
 Net increase/(decrease) in cash and cash equivalents                                        2,406     (7,328)
 Cash and cash equivalents at beginning of year                                              36,399    39,460
 Effect of movements in exchange rate                                                        (2,280)   4,267
 Cash and cash equivalents at end of year                                                    36,525    36,399

 

 

 

1.     Basis of preparation

These audited results have been prepared on the basis of the accounting
policies which are to be set out in Benchmark Holdings Plc's annual report and
financial statements for the year ended 30 September 2023. Those policies have
been consistently applied to all the years presented unless otherwise stated.

 

These Group and parent company financial statements were prepared and approved
by the Directors in accordance with (i) UK-adopted International Accounting
Standards and (ii) IFRS adopted pursuant to Regulation (EC) No. 1606/2002 as
it applied in the European Union ("Adopted IFRS"). While the financial
information included in this preliminary statement has been prepared on the
basis of the requirements of IFRSs in issue, this statement does not itself
contain sufficient information to comply with IFRS.

 

The financial information set out above does not constitute the company's
statutory accounts for the years ended 30 September 2023 or 2022 but is
derived from those accounts. Statutory accounts for 2022 have been delivered
to the registrar of companies, and those for 2023 will be delivered in due
course. The auditor has reported on those accounts. The auditor's reports for
2023 and for 2002 were both (i) unqualified and (ii) did not contain a
statement under section 498(2) or (3) of the Companies Act 2006.

 

The financial statements are prepared on the historical cost basis except that
the following assets and liabilities are stated at their fair value: certain
financial assets and financial liabilities (including contingent consideration
receivable and derivatives) and biological assets measured at fair value.
Non-current assets and disposal groups held for sale are stated at the lower
of previous carrying amount and fair value less costs to sell.

 

Going concern

As at 30 September 2023 the Group had net assets of £282.6m (2022: £323.3m),
including cash of £36.5m (2022: £36.4m) as set out in the Consolidated
Balance Sheet. The Group made a loss for the year of £21.6m (2022: £30.5m).

 

As noted in the Strategic Report, the business has performed steadily during
the year, showing resilience to some tough market conditions towards the end
of the year. The Directors have reviewed forecasts and cash flow projections
for a period of at least 12 months including downside sensitivity assumptions
in relation to trading performance across the Group to assess the impact on
the Group's trading and cash flow forecasts and on the forecast compliance
with the covenants included within the Group's financing arrangements.

 

In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduction in short-term treatment capacity. Key
downside sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and
removal of an additional financing opportunity within Genetics, along with
sensitivities on sales growth in revenues and pressure on pricing on CIS
artemia in Advanced Nutrition. Mitigating measures within the control of
management have been identified should they be required in response to these
sensitivities, including reductions in areas of discretionary spend, tight
control over new hires, deferral of capital projects and temporary hold on
R&D for non-imminent

products.

 

The refinancing exercise which commenced in FY22 was completed at the start of
FY23, so that adequate finance facilities are in place, and with financial
instruments in place to fix interest rates and opportunities available to
mitigate globally high inflation rates, the Group continues to show resilience
against current global economic pressures. The Directors are therefore
confident that even under all of the above sensitivity analysis, the Group has
sufficient liquidity and resources throughout the period under review whilst
still maintaining adequate headroom against the borrowing covenants. They
therefore remain confident that the Group has adequate resources to continue
to meet its liabilities as and when they fall due within the period of 12
months from the date of approval of these financial statements. Based on their
assessment, the Directors believe it remains appropriate to prepare the
financial statements on a going concern basis.

 

2.     Segment information

Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.

 

The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:

-       Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova.

-       Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.

-       Health -the segment focuses on providing health products to the
global aquaculture market.

 

In order to reconcile the segmental analysis to the Consolidated Income
Statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.

 

Measurement of operating segment profit or loss

Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy was
applied consistently throughout the current and prior period.

 

                                                                     Genetics  Advanced Nutrition  Health    Corporate  Inter-segment  Total

                                                                     £000      £000                £000      £000       sales          £000

 Year ended 30 September 2023                                                                                           £000
 Revenue                                                             65,791    78,503              25,514    5,747      (5,811)        169,744
 Cost of sales                                                       (35,876)  (34,704)            (13,173)  -          54             (83,699)
 Gross profit / (loss)                                               29,915    43,799              12,341    5,747      (5,757)        86,045
 Research and development costs                                      (3,778)   (2,071)             (279)     -          -              (6,128)
 Operating costs                                                     (11,696)  (23,354)            (7,290)   (9,064)    5,757          (45,647)
 Share of profit of equity-accounted investees, net of tax           (32)      -                   -         -          -              (32)
 Adjusted EBITDA                                                     14,409    18,374              4,772     (3,317)    -              34,238
 Exceptional - restructuring/acquisition and disposal related items  (3,913)   (920)               (509)     (2,475)    -              (7,817)
 EBITDA                                                              10,496    17,454              4,263     (5,792)    -              26,421
 Depreciation and impairment                                         (4,703)   (2,437)             (11,559)  (14)       -              (18,713)
 Amortisation and impairment                                         (1,894)   (14,269)            (2,329)   (3)        -              (18,495)
 Operating profit / (loss)                                           3,899     748                 (9,625)   (5,809)    -              (10,787)
 Finance cost                                                                                                                          (15,082)
 Finance income                                                                                                                        7,670
 Loss before tax                                                                                                                       (18,199)

 

                                                                     Genetics         Advanced Nutrition      Health       Corporate     Inter-segment     Total

                                                                     £000             £000                    £000         £000          sales             £000

 Year ended 30 September 2022                                                                                                            £000
 Revenue                                                             58,008    80,286             20,135             5,120        (5,272)         158,277
 Cost of sales                                                       (25,971)  (37,733)           (11,544)           4            95              (75,149)
 Gross profit / (loss)                                               32,037    42,553             8,591              5,124        (5,177)         83,128
 Research and development costs                                      (4,329)   (1,990)            (372)              -            -               (6,691)
 Operating costs                                                     (11,133)  (21,546)           (8,111)            (9,048)      5,177           (44,661)
 Share of profit of equity-accounted investees, net of tax           (595)     -                  -                  -            -               (595)
 Adjusted EBITDA                                                     15,980    19,017             108                (3,924)      -               31,181
 Exceptional - restructuring/acquisition and disposal related items  -         (220)              18                 218          -               16
 EBITDA                                                              15,980    18,797             126                (3,706)      -               31,197
 Depreciation and impairment                                         (5,322)   (2,236)            (12,251)           (88)         -               (19,897)
 Amortisation and impairment                                         (1,695)   (15,000)           (2,463)            (3)          -               (19,161)
 Operating profit / (loss)                                           8,963     1,561              (14,588)           (3,797)      -               (7,861)
 Finance cost                                                                                                                                     (20,057)
 Finance income                                                                                                                                   4,741
 Loss before tax                                                                                                                                  (23,177)

 

Non-current assets by location of assets

 

                 2023     2022

                 £000     £000
 Belgium         144,344  173,136
 Norway          74,541   83,752
 UK              29,690   42,373
 Iceland         37,631   39,448
 Rest of Europe  1,017    953
 Rest of world   34,047   38,543
                 321,270  378,204

 

 

3.     Net finance costs

                                                                       2023      2022

 Continuing operations                                                 £000      Restated

                                                                                 £000
 Interest received on bank deposits                                    627       319
 Foreign exchange gains on financing activities                        158       4,422
 Foreign exchange gains on operating activities                        4,709     -
 Cash flow hedges - ineffective portion of changes in fair value       2,176     -
 Finance income                                                        7,670     4,741
 Leases (interest portion)                                             (1,620)   (1,580)
 Cash flow hedges - re-classified from OCI                             -         (2,546)
 Cash flow hedges - in-effective portion of changes in fair value      -         (4,475)
 Foreign exchange losses on operating activities                       (4,547)   (1,620)
 Interest expense on financial liabilities measured at amortised cost  (8,881)   (9,672)
 Finance costs                                                         (15,048)  (19,893)
 Net finance costs recognised in profit or loss                        (7,378)   (15,152)

 

4.     Exceptional items - restructuring, acquisition and disposal related
items

Items that are material because of their nature, non-recurring or whose
significance is sufficient to warrant separate disclosure and identification
within the consolidated financial statements are referred to as exceptional
items. The separate reporting of exceptional items helps to provide an
understanding of the Group's underlying performance.

                                  2023    2022

                                  £000    £000
 Acquisition related items        652     -
 Exceptional restructuring costs  3,470   1,229
 Disposal related items           (218)   (1,245)
 Total exceptional items          3,904   (16)

 

Acquisition related items comprise fees incurred in the year in connection
with an aborted acquisition.

Exceptional costs include: £2,598,000 (2022: £843,000) of legal and
professional costs in relation to preparing for listing the Group on the Oslo
stock exchange, and £872,000 (2022: £276,000) relating to restructuring
costs.

 

Disposal related items include a credit of £235,000 (2022: £1,203,000) in
relation to additional contingent consideration received and receivable from
disposals in previous years (£294,000 relating to the disposal of Aquaculture
UK on 7 February 2020, and £909,000 relating to the disposal of Improve
International Limited and its subsidiaries on 23 June 2020) together with
legal fees, lease costs and disposal items (net of proceeds received)
totalling £17,000 relating to additional costs and disposals proceeds
relating to disposals that occurred in 2020.

 

5.     Discontinued operations

 

During the year, the group divested its tilapia business for consideration of
USD 1 in a management buy out. Consequently, these operations have been
classified as discontinued in the current year with a corresponding
restatement of the consolidated income statement and OCI for the year ended 30
September 2022 to reflect these changes.

 

Summary of restatement of FY22 results as reported in FY22 financial
statements

 

 

                                                        Continuing operations                                       Discontinued operations
                                                        Revenue   Adjusted EBITDA  Loss from continuing operations  Loss from discontinued operations

                                                        £000      £000             £000                             £000
 As stated in financial year 2022 financial statements  158,277   31,181           (30,451)                         -
 Reclassified in financial year 2023                    (570)     1,425            1,800                            (1,800)
 As stated in financial year 2023 financial statements  157,707   32,606           (28,651)                         (1,800)

 

 

 

                                        2023     Restated

                                        £000     2022

                                                 £000
 Revenue                                268      570
 Cost of sales                          (973)    (1,372)
 Gross profit                           (705)    (802)
 Research and development costs         (59)     (57)
 Other operating costs                  (490)    (566)
 Adjusted EBITDA                        (1,254)  (1,425)
 Exceptional loss on disposal           (3,913)  -
 EBITDA                                 (5,167)  (1,425)
 Depreciation and impairment            (304)    (205)
 Operating loss / Loss before taxation  (5,471)  (1,630)
 Net finance costs                      (34)     (164)
 Loss before taxation                   (5,505)  (1,794)
 Tax on loss                            -        (6)
 Loss from discontinued operations      (5,505)  (1,800)

 

Exceptional items within discontinued operations

                                               2022

                                       2023    Restated

                                       £000    £000
 Loss on disposal of trade and assets  3,774   -
 Other costs relating to disposals     139     -
 Total exceptional loss on disposal    3,913   -

 

Cash flows from discontinued operations

                                             2023     2022

                                             £000     £000
 Net cash flow from operating activities     (1,609)  (1,312)
 Net cash flow from investing activities     (27)     (341)
 Net cash flow from financing activities     (106)    77
 Net cash flow from discontinued operations  (1,742)  (1,576)

 

Results from discontinued operations by segment

The results from discontinued operations relate solely to the Genetics
operating segment.

 

Impact on the Group Consolidated Income Statement for the year ended 30
September 2023

 

                                                                      2023         2023           2023

                                                                      Continuing   Discontinued   Total

                                                                      £000         £000           £000
 Revenue                                                              169,476      268            169,744

 Cost of sales                                                        (82,726)     (973)          (83,699)
 Gross profit                                                         86,750       (705)          86,045
 Research and development costs                                       (6,069)      (59)           (6,128)
 Other operating costs                                                (45,157)     (490)          (45,647)
 Share of profit of equity-accounted investees, net of tax            (32)         -              (32)
 Adjusted EBITDA                                                      35,492       (1,254)        34,238
 Exceptional - restructuring, acquisition and disposal related items  (3,904)      (3,913)        (7,817)
 EBITDA                                                               31,588       (5,167)        26,421
 Depreciation and impairment                                          (18,409)     (304)          (18,713)
 Amortisation and impairment                                          (18,495)     -              (18,495)
 Operating loss                                                       (5,316)      (5,471)        (10,787)
 Net finance costs                                                    (7,378)      (34)           (7,412)
 Loss before taxation                                                 (12,694)     (5,505)        (18,199)
 Tax on loss                                                          (3,365)      -              (3,365)
 Loss after tax for the financial period                              (16,059)     (5,505)        (21,564)

 

Impact on the Group Consolidated Income Statement for the year ended 30
September 2022

 

                                                                      2022                  2022           2022

                                                                      Continuing Restated   Discontinued   Total

                                                                      £000                  Restated       Restated

                                                                                            £000           £000
 Revenue                                                              157,707               570            158,277
 Cost of sales                                                        (73,777)              (1,372)        (75,149)
 Gross profit                                                         83,930                (802)          83,128
 Research and development costs                                       (6,634)               (57)           (6,691)
 Other operating costs                                                (44,095)              (566)          (44,661)
 Share of profit of equity-accounted investees, net of tax            (595)                 -              (595)
 Adjusted EBITDA                                                      32,606                (1,425)        31,181
 Exceptional - restructuring, acquisition and disposal related items  16                    -              16
 EBITDA                                                               32,622                (1,425)        31,197
 Depreciation and impairment                                          (19,692)              (205)          (19,897)
 Amortisation and impairment                                          (19,161)              -              (19,161)
 Operating loss                                                       (6,231)               (1,630)        (7,861)
 Net finance costs                                                    (15,152)              (164)          (15,316)
 Loss before taxation                                                 (21,383)              (1,794)        (23,177)
 Tax on loss                                                          (7,268)               (6)            (7,274)
 Loss after tax for the financial period                              (28,651)              (1,800)        (30,451)

 

Effects of business disposals on the financial position of the Group

On 30 September, the tilapia businesses of a Group's subsidiary was disposed
of for consideration of USD 1. The assets sold are

highlighted in the table below.

 

                                                                Tilapia

                                                                £000
 Assets
 Property, plant and equipment (including Right of use assets)  738
 Intangible assets                                              3,036
 Net assets and liabilities                                     3,774
 Total consideration                                            -
 Consideration received in cash                                 -
 Cash and cash equivalents disposed of                          -
 Net cash inflow/(outflow)                                      -

 

 

6.     Loss per share

 

Basic loss per share is calculated by dividing the profit or loss attributable
to ordinary equity holders of the Company by the

weighted average number of ordinary shares in issue during the period.

 

                                                            2023                                2022
                                                            Continuing  Discontinued  Total     Continuing  Discontinued  Total
 Loss attributable to equity holders of the parent (£000)   (17,641)    (5,505)       (23,146)  (30,287)    (1,800)       (32,087)
 Weighted average number of shares in issue (thousands)                               731,935                             698,233
 Basic loss per share (pence)                               (2.41)      (0.75)        (3.16)    (4.34)      (0.26)        (4.60)

 

Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value based on the monetary value of the
subscription rights attached to outstanding share options and warrants.

 

A total of 8,948,132 (2022: 6,240,304) potential ordinary shares have not been
included within the calculation of statutory diluted loss per share for the
year as they are anti-dilutive and reduce the loss per share. However, these
potential ordinary shares could dilute earnings per share in the future. The
diluted and basic loss per share are the same for both continuing and
discontinued.

 

 

7.     Property, plant and equipment

 

Group

 

                                                                     Freehold Land and Buildings  Assets in the course of construction  Long-Term Leasehold Property  Plant and Machinery  Office Equipment and Fixtures  Total

                                                                     £000                         £000                                  Improvements                  £000                 £000                           £000

                                                                                                                                        £000
 Cost
 Balance at 1 October 2021                                           63,027                       1,807                                 6,421                         32,893               2,751                          106,899
 Additions                                                           4,025                        1,616                                 283                           4,546                338                            10,808
 Increase/(decrease) through transfers from assets in the course of  251                          (1,275)                               -                             995                  29                             -
 construction
 Exchange differences                                                1,924                        116                                   432                           2,377                146                            4,995
 Transfer to inventory                                               -                            -                                     -                             (1,514)              -                              (1,514)
 Disposals                                                           (224)                        -                                     -                             (131)                (126)                          (481)
 Disposals through sale of subsidiary                                -                            -                                     -                             -                    -                              -
 Balance at 30 September 2022                                        69,003                       2,264                                 7,136                         39,166               3,138                          120,707
 Balance at 1 October 2022                                           69,003                       2,264                                 7,136                         39,166               3,138                          120,707
 Additions                                                           2,164                        560                                   28                            2,662                539                            5,953
 On acquisition                                                      -                            -                                     -                             315                  -                              315
 Reclassification                                                    56                           (106)                                 -                             50                   -                              -
 Increase/(decrease) through transfers from
 assets in the course of construction                                877                          (1,556)                               -                             679                  -                              -
 Exchange differences                                                (4,446)                      (53)                                  (344)                         (1,670)              (328)                          (6,841)
 Transfer to assets held for sale                                    (1,392)                      -                                     -                             -                    -                              (1,392)
 Transfer from inventory                                             -                            -                                     -                             94                   -                              94
 Balance at 30 September 2023                                        66,181                       1,109                                 5,245                         39,175               3,291                          115,001
 Accumulated depreciation
 Balance at 1 October 2022                                           7,829                        -                                     4,723                         14,806               761                            28,119
 Depreciation charge for the year                                    2,387                        -                                     197                           5,411                607                            8,602
 Exchange differences                                                792                          -                                     256                           1,200                141                            2,389
 Disposals                                                           (84)                         -                                     -                             (102)                (117)                          (303)
 Balance at 30 September 2022                                        10,924                       -                                     5,176                         21,315               1,392                          38,807
 Balance at 1 October 2022                                           10,924                       -                                     5,176                         21,315               1,392                          38,807
 Depreciation charge for the year                                    2,266                        -                                     79                            5,513                595                            8,453
 Transfer to assets held for sale                                    (542)                        -                                     -                             -                    -                              (542)
 Exchange differences                                                (908)                        -                                     (189)                         (810)                (214)                          (2,121)
 Disposals                                                           (81)                         -                                     (1,575)                       (1,323)              (28)                           (3,007)
 Balance at 30 September 2023                                        11,659                       -                                     3,491                         24,695               1,745                          41,590
 Net book value
 At 30 September 2023                                                54,522                       1,109                                 1,754                         14,480               1,546                          73,411
 At 30 September 2022                                                58,079                       2,264                                 1,960                         17,851               1,746                          81,900
 At 1 October 2021                                                   55,198                       1,807                                 1,698                         18,087               1,990                          78,780

 

 

 

8.     Leases

 

Group

                                2023    2022

 Right-of-use-assets            £000    £000
 Leasehold property             9,213   9,389
 Plant and machinery            10,585  17,582
 Office equipment and fixtures  6       63
                                19,804  27,034

 Lease liabilities              2023    2022

                                £000    £000
 Current                        11,567  11,522
 Non-current                    8,293   14,765
                                19,860  26,287

 

 Depreciation charge of right-of-use assets           2023    2022

                                                      £000    £000
 Leasehold property                                   1,210   1,383
 Plant and machinery                                  9,038   9,176
 Office equipment and fixtures                        12      72
                                                      10,260  10,631

 Additional information                               2021    2020

                                                      £000    £000
 Additions to right-of-use assets                     2,120   497
 Modifications to right-of-use assets                 1,697   10,884
 Impairment of leasehold property right-of-use asset  -       664
 Interest expense                                     1,654   1,744
 Expense relating to short-term leases                237     152
 Expense relating to leases of low-value leases       20      151
 Total cash outflow for leases                        9,438   10,533

 

Benchmark Animal Health Limited modified the existing leases for two PSV
vessels, the FS Aquarius and the FS Pegasus to extend the lease term only.
These two assets constitute £8,405,000 of the net book value and £9,374,000
of the lease liability at the year end.

 

 

9.     Intangible assets

Group

 

                                             Websites  Goodwill  Patents and Trademarks  Intellectual Property  Customer Lists  Contracts  Licences  Genetics  Development costs  Total

                                             £000      £000      £000                    £000                   £000            £000       £000      £000      £000               £000
 Cost or valuation
 Balance at 1 October 2021                   319       140,055   338                     133,201                5,271           6,602      34,479    22,636    27,579             370,480
 Additions - externally acquired             94        -         111                     -                      -               -          -         -         -                  205
 Additions - internally developed            -         -         -                       -                      -               -          -         -         1,708              1,708
 Exchange differences                        34        24,619    3                       27,206                 1,107           (27)       5,841     599       1,935              61,317
 Balance at 30 September 2022                447       164,674   452                     160,407                6,378           6,575      40,320    23,235    31,222             433,710
 Balance at 1 October 2022                   447       164,674   452                     160,407                6,378           6,575      40,320    23,235    31,222             433,710
 Additions - on acquisition                  -         -         -                       -                      -               -          -         -         -                  -
 Additions - externally acquired             80        1         115                     -                      -               -          -         -         -                  196
 Additions - internally developed            -         -         -                       -                      -               -          -         -         632                632
 Disposals                                   -         (3,036)   (21)                    -                      -               -          (150)     -         -                  (3,207)
 Reclassification to assets held for resale  -         -         -                       -                      -               -          -         -         -                  -
 Exchange differences                        (15)      (13,682)  (1)                     (13,737)               (559)           (70)       (3,186)   (1,267)   (982)              (33,499)
 Balance at 30 September 2023                512       147,957   545                     146,670                5,819           6,505      36,984    21,968    30,872             397,832
 Accumulated amortisation and impairment
 Balance at 1 October 2021                   67        41,358    133                     73,541                 1,166           6,210      13,077    4,111     1,777              141,440
 Amortisation charge for the period          67        -         70                      13,574                 215             102        2,027     636       2,165              18,856
 Impairment                                  -         -         -                       305                    -               -          -         -         -                  305
 Exchange differences                        9         8,592     3                       16,966                 275             (19)       1,839     139       41                 27,845
 Balance at 30 September 2022                143       49,950    206                     104,386                1,656           6,293      16,943    4,886     3,983              188,446
 Balance at 1 October 2022                   143       49,950    206                     104,386                1,656           6,293      16,943    4,886     3,983              188,446
 Amortisation charge for the period          85        -         91                      12,605                 222             94         1,818     606       2,437              17,958
 Impairment                                  -         1         -                       61                     -               -          476       -         -                  538
 Disposals                                   -         -         (21)                    -                      -               -          (150)     -         -                  (171)
 Exchange differences                        (4)       (4,484)   (2)                     (8,868)                (143)           (52)       (1,177)   (253)     (33)               (15,016)
 Balance at 30 September 2023                224       45,467    274                     108,184                1,735           6,335      17,910    5,239     6,387              191,755
 Net book value
 At 30 September 2023                        288       102,490   271                     38,486                 4,084           170        19,074    16,729    24,485             206,077
 At 30 September 2022                        304       114,724   246                     56,021                 4,722           282        23,377    18,349    27,239             245,264
 At 1 October 2021                           252       98,697    205                     59,660                 4,105           392        21,402    18,525    25,802             229,040

 

The table below provides further detail of intangibles and their remaining
amortisation period.

 

                                                                                                              NBV 2023  NBV 2022  Remaining life

 Description                                                                 Category                         £000      £000      2023
 Acquisition of INVE in 2015
 Goodwill                                                                    Goodwill                         79,909    87,585    -
 Harvesting rights                                                           Licences                         19,029    22,449    12
 Product technology                                                          Intellectual property            -         446       -
 Product rights                                                              Intellectual property            24,880    39,390    2
 Brand names                                                                 Intellectual property            10,945    12,976    12
 In-process R&D                                                              Intellectual property            535       847       2
 Customer relationships                                                      Customer lists                   4,085     4,723     18
 Total relating to acquisition of INVE                                                                        139,383   168,416   -
 Acquisition of Salmobreed AS (Now part of Benchmark Genetics Norway AS) in
 2014
 Goodwill                                                                    Goodwill                         6,063     6,523     -
 Genetic material and breeding nuclei                                        Genetics                         8,926     9,911     31
 Total relating to acquisition of Salmobreed AS                                                               14,989    16,434    -
 Acquisition of Stofnfiskur( Now Benchmark Genetics Iceland) in

 2014
 Goodwill                                                                    Goodwill                         11,999    12,467    -
 Genetic material and breeding nuclei                                        Genetics                         7,598     8,147     31
 Total relating to acquisition of Stofnfiskur                                                                 19,597    20,614    -
 Acquisition of Akvaforsk Genetics Center AS (Now part of
 Benchmark Genetics Norway AS) in 2015
 Goodwill                                                                    Goodwill                         4,520     7,348     -
 Licences                                                                    Licences                         -         292       -
 Contracts                                                                   Contracts                        170       282       2
 Total relating to acquisition of Akvaforsk Genetics Center AS                                                4,690     7,922     -
 Capitalised development costs

                                                                                                                                  8

                                                                                                                                  Not yet ready

                                                                                                                                  for use
 Ectosan®Vet/CleanTreat®                                                     Development costs                14,048    15,840
 Live food alternative diets                                                 Development costs                3,879     4,115
 SPR Shrimp                                                                  Development costs                5,453     6,686     8
 Total capitalised development costs                                                                          23,380    26,641
 Other purchased material intangible assets                                  Intellectual Property            1,408     1,497     16
 Total relating to other purchased intangible assets                                                          1,408     1,497
 Other individually immaterial goodwill and intangibles                                                       2,630     3,740
 Total net book value at 30 September                                                                         206,077   245,264

 

 

10.   Impairment testing of goodwill and other intangible assets

 

The Group tests goodwill and other intangibles not yet ready for use annually
for impairment, or more frequently if there are indications that goodwill or
the other intangible assets might be impaired. Goodwill acquired in a business
combination is allocated, at acquisition, to the cash generating units (CGUs)
that are expected to benefit from the business combination. The only
intangible assets not yet ready for use are generally the capitalised
development costs on internally developed products. The development costs
included in the table below represents only those that are not yet ready for
use.

 

Due to the interdependence of the operations within each of the business areas
and the way in which they are managed, management have determined the CGUs are
the business areas themselves - Health, Genetics and Advanced Nutrition. These
are the smallest groups of assets that independently generate cashflows and
whose cashflows are largely independent of those generated by other assets.
Goodwill and capitalised development costs arise across the Group, and are
allocated specifically against the CGUs as follows:

 

                                                            Genetics  Advanced Nutrition

                                                            2023      2023                Total

                                                            £000      £000                2023

                                                                                          £000
 Benchmark Genetics AS                                      6,062     -                   6,062
 Benchmark Genetics Iceland HF (Previously Stofnfiskur HF)  11,999    -                   11,999
 Akvaforsk Genetic Center*                                  4,520     -                   4,520
 INVE Aquaculture Group                                     -         79,909              79,909
 Goodwill                                                   22,581    79,909              102,490
 Development costs                                          -         3,879               3,879

*  Includes goodwill arising from the joint acquisition of Akvaforsk Genetics
Center AS (which was transferred into Benchmark Genetics Norway AS) and
Benchmark Genetics USA Inc (formerly Akvaforsk Genetics Center Inc).

 

                                                                       Advanced

                                                            Genetics   Nutrition   Total

                                                            2022       2022        2022

                                                            £000       £000        £000
 Benchmark Genetics AS                                      6,522      -           6,522
 Benchmark Genetics Iceland HF (Previously Stofnfiskur HF)  12,467     -           12,467
 Akvaforsk Genetic Center*                                  8,150      -           8,150
 INVE Aquaculture Group                                     -          87,585      87,585
 Goodwill                                                   27,139     87,585      114,724
 Development costs                                          -          4,115       4,115

*  Includes goodwill arising from the joint acquisition of Akvaforsk Genetics
Center AS (which was transferred into Benchmark Genetics Norway AS) and
Benchmark Genetics USA Inc (formerly Akvaforsk Genetics Center Inc).

 

The recoverable amounts of the above CGUs have been determined from
value-in-use calculations. These calculations used Board approved cash flow
projections from five-year business plans based on actual operating results
and current forecasts. These forecasts were then extrapolated into perpetuity
taking account of specific terminal growth rates for future cash flows, using
individual business operating margins based on past experience and future
expectations in light of anticipated economic and market conditions. The
pre-tax cash flows that these projections produced were discounted at pre-tax
discount rates based on the Group's beta adjusted cost of capital, further
adjusted to reflect management's assessment of specific risks related to the
markets and other factors pertaining to each CGU. Forecasts also include any
costs in relation to the Group's climate change strategy and climate change
factors have been considered when setting the long-term growth rates.

 

The values assigned to the key assumptions represent management's assessment
of future trends in the relevant industries and have been based on historical
data from both external and internal sources.

 

Genetics

The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 15.7% (2022: 14.7%). CAGR of revenue of 9% (2022:
15%) is implied by the five-year plan and a long-term growth rate of 2.5%
(2022: 2.5%) has been used to extrapolate the terminal year cashflow into
perpetuity.

 

Having conducted a sensitivity analysis of key assumptions, no reasonably
possible changes that would result in the elimination

of all headroom were identified.

 

Advanced Nutrition

The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 16.4% (2022: 15.6%). CAGR of revenue of 12% (2022:
10%) is implied by the five-year plan and a long-term growth rate of 3.5%
(2022: 3.5%) has been used to extrapolate the terminal year cashflow into
perpetuity. Market analysis reports predict long-term growth rates of c.5.0%,
and the health benefits of shrimp are still very much in evidence. Management
believes that a long-term growth rate of 3.5% represents both a prudent and
consistent approach for the CGU.

 

Sensitivity analysis has been performed on the key assumptions. Reducing the
forecast growth rates for less mature parts of the CGU within Health and Diets
products did not result in elimination of headroom. However, the forecasts
growth rates for the CGU include an assumption around the ongoing recovery in
global shrimp markets, and if that recovery is slower than the forecasts
anticipate, due to factors such as continued reduced end market demand for
Shrimp, to the extent that the CAGR of revenue implied over the five-year plan
falls to 9%, this would result in a potential impairment.

 

The sensitivity to movements in the terminal growth rate and discount rate
were also assessed, and a reduction in terminal growth rate from 3.5% to 1.5%,
or an increase in the discount rate from 16.4% to 18.4%, either of which are
considered to be reasonably possible, would reduce the headroom on the
Advanced Nutrition CGU of £31.6m to nil. Should the growth rate reduce or
discount rate increase further than this, then an impairment would be likely.

 

Health

The pre-tax cashflows from the five-year projections were discounted using a
pre-tax discount rate of 17.4% (2022: 16.4%). An assumed CAGR of revenue of
23% (2022: 27%) in the five-year plan reflects the importance of the
successful commercial ramp- up of the business area's new sea lice treatment
in the forecast period. A long-term growth rate of 0.0% (2022: 0.0%) has been
used to extrapolate the terminal year cashflow into perpetuity. The prudent
assumption in the long-term growth rate is intended to reflect that the
business area's new sea lice treatment is the principal source of cash
generation, and only benefits from patent protection against generic
competitors for a finite period of time.

 

The valuation of the Health cash generating unit indicates sufficient headroom
such that a reasonably possible change to key assumptions is unlikely to
result in an impairment in related development costs.

 

11.   Biological assets

Book value of biological assets recognised at fair value

 

 Group                                 2023    2022

                                       £000    £000
 Salmon eggs                           10,631  14,037
 Salmon broodstock                     33,411  30,501
 Salmon milt                           796     606
 Lumpfish fingerlings                  757     1,090
 Shrimp                                397     424
 Total biological assets 30 September  45,992  46,658
 Analysed as
 Current                               27,586  25,780
 Non-current                           18,406  20,878
 Total biological assets 30 September  45,992  46,658

 

Change in book value of biological assets

 

                                                         2023      2022

                                                         £000      £000
 Biological assets 1 October Increase                    46,658    38,365
 Increase from production                                42,393    48,067
 Reduction due to sales                                  (40,583)  (45,535)
 Other movements in biological assets                    1,810     4,532
 Foreign exchange movement before fair value adjustment  (1,562)   1,704
 Change in fair value through income statement           (103)     1,595
 Foreign exchange impact on fair value adjustment        (811)     462
 Biological assets 30 September                          45,992    46,658

 

Assumptions used for determining fair value of biological assets

IAS 41 requires that biological assets are accounted for at the estimated fair
value net of selling and harvesting costs. Fair value is measured in
accordance with IFRS 13 and is categorised into levels in the fair value
hierarchy.

 

The fair value inputs for salmon eggs are categorised as level 2. The
calculation of the fair value of the salmon eggs is based upon the current
seasonally adjusted selling prices for salmon eggs less transport and
incubation costs and taking account of the market capacity. The valuation also
takes account of the mortality rates of the eggs and expected life as sourced
from internally generated data.

 

The fair value inputs for salmon broodstock are categorised as level 3. The
broodstock contain generations of genetic improvements and cannot be valued
purely on the market weight of salmon. The Group does not sell its broodstock
commercially so there is no observable input in this respect. Therefore, the
calculation of the estimated fair value of salmon broodstock is primarily
based upon its main harvest output being salmon eggs, which are priced upon
the current seasonally adjusted selling prices for the Group's salmon eggs.
These prices are reduced for harvesting costs, freight costs, incubation costs
and market capacity to arrive at the net value of broodstock. The valuation
also reflects the internally generated data to arrive at the biomass.

 

This includes the weight of the broodstock, the yield that each kilogram of
fish will produce and mortality rates. The fish take four years to reach
maturity, and the age and biomass of the fish is taken into account in the
fair value. Finally, the valuation takes account of future expected sales
volumes.

 

Change in book value of salmon broodstock

                                                         2023      2022

                                                         £000      £000
 Biological assets 1 October                             30,501    26,700
 Increase from production                                25,494    28,720
 Transfer to salmon eggs following harvesting            (22,677)  (26,509)
 Foreign exchange movement before fair value adjustment  (1,199)   1,326
 Change in fair value through income statement           1,853     (31)
 Foreign exchange impact on fair value adjustment        (561)     295
 Biological assets 30 September                          33,411    30,501

 

Significant unobservable inputs used in the valuation of salmon broodstock

                                                2023     2022
 Number of eggs valued in broodstock (m units)  250      222
 Average selling price per egg (GBP)            0.131    0.135
 Future costs per egg (GBP)                     (0.016)  (0.021)

 

The fair value inputs for lumpfish fingerlings and shrimp are categorised as
level 2. The calculation of the fair value of lumpfish fingerlings and shrimp
is valued on current selling prices less transport costs. Internally generated
data is used to incorporate mortality rates and the weight of the biomass.

 

The fair value inputs for lumpfish fingerlings and shrimp are categorised as
level 2. The calculation of the fair value of lumpfish fingerlings and shrimp
is valued on current selling prices less transport costs. Internally generated
data is used to incorporate mortality rates and the weight of the biomass.

 

The fair value inputs for salmon milt are categorised as level 3. Where we
have identified individual salmon carrying particular traits or disease
resistance, semen (milt) can be extracted and deep-frozen using
cryopreservation techniques (the process of freezing biological material at
extreme temperatures in liquid nitrogen). The calculation of the fair value of
milt is based on production and freezing costs and, where appropriate, an
uplift to recognise the additional selling price that can be achieved from
eggs fertilised by premium quality milt.

 

There is a presumption that fair value can be measured reliably for a
biological asset. However, we sometimes face a situation where alternative
estimates of fair value are determined to be clearly unreliable (for example,
where we establish a new broodstock farm in a new territory). In such a case,
that biological asset shall be measured at its cost less any accumulated
impairment losses. In the year this applied to £2,150,000 of broodstock in
Chile. As at 30 September the gross carrying amount was £5,186,000 (2022:
£4,704,000) and the accumulated impairment losses were £3,036,000 (2022:
£2,735,000).The valuation models by their nature are based upon uncertain
assumptions on sales prices, market capacity, weight, mortality rates, yields
and assessment of the discounts to reflect the stages of maturity. The Group
has a degree of expertise in these assumptions but these assumptions are
subject to change. Relatively small changes in assumptions would have a
significant impact on the valuation. A 1% increase/decrease in the assumed
selling price per egg would increase/decrease the fair value of salmon
broodstock and eggs by £440,000. A 10% increase/decrease in the biomass of
salmon broodstock and the quantity of salmon eggs valued would
increase/decrease the fair value of those biological assets by £4,404,000.

 

The Group is exposed to financial risks arising from changes in the market
value of the salmon eggs, lumpfish fingerlings and shrimp broodstock that it
sells. The Group does not anticipate that prices will decline significantly in
the foreseeable future and, therefore, has not entered into derivative or
other contracts to manage the risk of a decline in the price of its products.
The Group reviews its outlook for salmon eggs, lumpfish fingerlings and shrimp
broodstock prices regularly in considering the need for active financial risk
management.

 

Risk management strategy related to aquaculture activity

The Group is exposed to the following risks relating to its aquaculture
activities. These risks and management's strategies to mitigate them are
described below:

 

Regulatory and environmental risks

The nature of certain of the Group's operating activities exposes us to
certain significant risks to the environment, such as incidents associated
with releases of chemicals or hazardous substances when conducting our
operations, which could result in liability, fines, risk to our product
permissions and reputational damage. There is a risk that natural disasters
could lead to damage to infrastructure, loss of resources, products or
containment of hazardous substances. Our business activities could be
disrupted if we do not respond, or are perceived not to respond, in an
appropriate manner to any major crisis or if we are not able to restore or
replace critical operational capacity.

 

In mitigation we have implemented standards and requirements which govern key
risk management activities such as inspection, maintenance, testing, business
continuity and crisis response.

 

 

Biological risks

The Group is exposed to the risk of disease within the Group's own operations
and disease in the market resulting in possible border closures. In
mitigation, the Group:

·   Operates the highest levels of biosecurity.

·   Holds genetic stock at multiple sites and increasingly sources from its
own land-based salmon breeding facilities.

·   Operates containment zones which mitigates the risk of border closures
affecting its ability to import or export.

·   Has placed increased focus on insuring its biological stock.

 

Outputs and quantities held

Total output of aquaculture activity in the year was:

                       2023          2022
 Salmon eggs           334.7m units  291.1m units
 Lumpfish fingerlings  1.5m units    2.0m units

 

Total quantities held at 30 September were:

                       2023          2022
 Salmon eggs           85.6m units   103.9m units
 Salmon broodstock     1,517 tonnes  1,737 tonnes
 Lumpfish fingerlings  0.4m units    0.7m units

 

12.   Trade and other receivables

 

                                                                            2023     2022

 Group                                                                      £000     £000
 Trade receivables                                                          27,460   31,218
 Less: provision for impairment of trade receivables                        (2,612)  (2,748)
 Trade receivables - net                                                    24,848   28,470
 Total financial assets other than cash and cash equivalents measured at    24,848   28,470
 amortised cost
 Other receivables - contingent consideration                               -        887
 Total financial assets other than cash and cash equivalents classified as
 measured at fair value through
 profit and loss                                                            -        887
 Prepayments                                                                18,081   14,989
 Other receivables                                                          16,866   12,031
 Total trade and other receivables                                          59,795   56,377

 

Other receivables relate to the following items: VAT recoverable £4,353,000
(2022: £4,386,000), research and development expenditure tax credits and
similar items £157,000 (2022: £154,000), the right to receive an agreed
proportion of a key supplier's harvest* £10,173,000 (2022: £5,249,200),
accrued income of £1,177,000 (2022: £1,377,000) and other amounts receivable
of £1,006,000 (2022: £865,000).

 

*A financial liability of £10,173,000 (2022: £5,249,200) is recognised
(within trade payables) for the amount invoiced and remaining outstanding at
the year-end in relation to the Group's contractual obligation to pay for a
specified share of the harvest of a supplier, regardless of delivery and
without recourse to the supplier. As at 30 September, as the Group has not
taken physical delivery of the harvested product and as the Group does not
control the harvested product, an 'other receivable' of £10,173,000 (2022:
£5,249,200) has been recorded in relation to the Group's right to receive the
product in the future.

 

The financial asset at fair value through profit and loss related to
contingent consideration outstanding from the disposal of Improve
International Limited in FY20. This related to deferred cash consideration
dependent on the delivery of certain future revenues in the financial year
ended 30 September 2022 and the fair value was derived from the likely
receivable amount based on expectations of performance against the targets.
The amount recovered in the financial year ended 30 September 2023 was not
materially different to management's estimate.

 

The fair values of trade and other receivables measured at amortised cost are
not materially different to their carrying values. As at 30 September 2023
trade receivables of £6,313,000 (2022: £5,943,000) were past due but not
impaired. They relate to customers with no default history. The ageing
analysis of these receivables is as follows:

 

 

                         2023    2022

                         £000    £000
 Up to 3 months overdue  5,480   5,761
 3 to 6 months overdue   833     218
 6 to 12 months overdue  -       (36)
                         6,313   5,943

 

Movements on the Group provision for impairment of trade receivables are as
follows:

                                  2023    2023

                                  £000    £000
 At 1 October                     2,748   2,493
 Provided during the year         696     281
 Unused provisions reversed       (600)   (180)
 Provisions used during the year  (32)    -
 Foreign exchange movements       (200)   154
 At 30 September                  2,612   2,748

 

The movement on the provision for impaired receivables has been included in
the operating costs line in the Consolidated Income Statement.

 

Other classes of financial assets included within trade and other receivables
do not contain impaired assets.

 

13. Trade and other payables

                                                                                 2023     2022

 Group                                                                           £000     £000
 Trade payables                                                                  26,657   22,149
 Other payables                                                                  2,213    1,127
 Accruals                                                                        16,257   17,636
 Other payables - tax and social security payments                               2,957    3,799
 Financial liabilities, excluding loans and borrowings, classified as financial  48,084   44,711
 liabilities measured at amortised cost
 Financial contracts - hedging instrument                                        5,683    8,012
 Financial liabilities, excluding loans and borrowings, classified as financial  5,683    8,012
 liabilities at fair value through profit or loss
 Deferred income                                                                 404      597
 Total trade and other payables                                                  54,171   53,320
 Less: non-current portion of other payables                                     (6,842)  (8,996)
 Current portion                                                                 47,329   44,324

Book values approximate to fair value at 30 September 2023 and 2022.

 

Of the financial contracts £6,155,000 (2022: £8,387,000) relates to a NOKUSD
floating to fixed cross-currency interest rate swap (CCS) and a NOK interest
rate swap (IRS), both of which were entered to fully match the timing and
tenor of the underlying new senior unsecured floating rate listed bond issue
of NOK 750m.

 

The floating-to-fixed NOK IRS (notional NOK 300m) is designated a cash flow
hedge where any changes in the fair value of the swap will be taken directly
to equity within the hedging reserve and recycled to profit or loss as the
bond impacts the profit or loss.

 

The NOKUSD CCS (notional NOK450m) has been separated into two synthetic swaps;
the first is a floating-to-fixed NOKGBP interest rate swap, being a cash flow
hedge of the foreign exchange and interest rate risk on NOK denominated debt.
The fair value of this synthetic swap is posted to the hedging reserve in
equity. The second synthetic swap is a fixed-to-fixed GBPUSD swap designated
as a net investment hedge in the USD net assets in the consolidated accounts
of Benchmark Holdings plc. The fair value of this leg is posted to the foreign
exchange translation reserve in equity.

 

14.   Loans and borrowings

Group

                               2023     2022

                               £000     £000
 Non-Current
 2025 750m NOK Loan notes      57,604   61,976
 Bank borrowings               16,799   17,226
 Unamortised debt issue costs  (742)    (922)
 Lease liabilities             8,293    14,765
                               81,954   93,045
 Current
 Bank borrowings               9,320    5,569
 Unamortised debt issue costs  (842)    -
 Lease liabilities             11,567   11,522
                               20,045   17,091
 Total loans and borrowings    101,999  110,136

At 30 September 2023 the fair value of the unsecured floating rate listed
green bond of NOK 750m was NOK 791m.

 

On 21 November 2022, the Group refinanced its USD15m RCF with a secured GBP20m
RCF provided by DNB Bank ASA, maturing on 27 June 2025. The margin on this
facility is a minimum of 2.75% and a maximum of 3.25%, dependent upon the
leverage of the Group above the relevant risk free reference or IBOR rates
depending on which currency is drawn.

 

Benchmark Genetics Salten AS had the following loans (which are ring-fenced
debt without recourse to the remainder of the Group) at 30 September 2023:

·      Term loan with a balance of NOK 171.9m provided by Nordea Bank
Norge Abp. The loan is a five-year term loan maturing no later than January
2028 at an interest rate of 2.5% above three-month NIBOR. This loan refinanced
the previous term loan from the same bank when the outstanding balance of NOK
162 million was repaid in February 2023.

·      NOK 20.0m 12-month working capital facility provided by Nordea
Bank Norge Abp. This was undrawn at 30 September 2023 (2022: undrawn).

·      Term loan with a balance of NOK 35.5m (2022: NOK 40.1m) provided
by Innovasjon Norge. The loan is a 12-and-a-half-year term loan maturing in
March 2031. The interest rate on this loan at 30 September 2023 was 7.45%. The
interest rate on this loan is variable.

·      A new term loan with a balance of NOK 10.0m provided by
Innovasjon Norge. The loan is a 15-year term loan maturing in July 2038. The
interest rate on this loan at 30 September 2023 was 7.45%. The interest rate
on this loan is variable.

·      NOK 21.75m loan provided by Salten Stamfisk AS (the minority
shareholder). The loan attracts interest at 2.5% above three month NIBOR and
is repayable on maturity of the Nordea term loan above.

 

The lease liabilities are secured on the assets to which they relate.

 

The currency profile of the Group's loans and borrowings is as follows:

                  2023     2022

                  £000     £000
 Sterling         16,680   19,697
 Norwegian Krone  76,730   81,634
 Thai Baht        464      954
 Euro             614      272
 US Dollar        6,460    6,888
 Icelandic Krone  585      545
 Other            466      146
                  101,999  110,136

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FR BKLBLXFLBFBV

Recent news on Benchmark Holdings

See all news